2023-03-31-accounts

Registered number: 04509293 Charity numboys: 1094231 & SC039257 The British Allergy Foundation (A company limiled by guarantee) Trustees. Teport and financlal statements For the year ended 31 Mar¢h 2023 1111 •ACIVSSTD• iY)112r2023

109

Th• Bfltlsh Allergy Foundation IA company limited by guarantee) Contents Page Reference and admlnbtraliv• detslls ofthe Charity, Its TNstees and advlser4 Trust¢os' r•part 2-14 Ind¢pendont auditots. report on lh fin4nci￿ statements 15-19 Consolidated statement of fil￿ncIal acdviil•s consol1da1￿ balanco she81 21 Charity balance sheet 22 Consol0dat￿ stalemenl ol cash flows 23 Nots$ to th• finnclal stat•ments 24-50

.The Brlllsh Allergy Foundation IA company limited by guarantsel Reference #nd administiatlvè d•taih of the Ch•rlty. its Trttste￿ and advlsws For lh• year end$d 31 Ma￿h 2023 Trnstees MS'L Prilthard, Chair Mrs A Tharani. C￿r Mr R Daby Mr R Dud-Southem MBE Mf P Frarnpton {wnted 29 Septemb8r 2022) Or B HevAiI MT J Redding 1￿$￿Jned 24 NoveM￿r 2022) Or G st￿les Dr S Kay¢de (appointed 24 Novwnber 2022) Ms R Ok4royd {appo¢nled 23 Febwary 2023) Ms K Sykes lappointed 17 June 2023) Ms E Withers (appointed 24 November 2022) Company regi$t¢r¢d number 04509293 Charlty reglslerod numbers 1094231 aTrJ SC039257 R•gistered office London 14ouse Business Centre Thames Roal Crayford Dartlord Englar DA14SL Company sttr¢tary P Turrull Chlef executivo olfic•r S Miles Independent auditors Kre51on Reeves LLP ChartEYed A¢¢ounlants ststutory Audrtor 37 Sl Mar9arefs Street Canlerbury Kent CT12TU Page 1

Th¢ British Allergy Foundation IA company lim11￿ by guarantee) Trust¢•s' r•port For the year nd•d 31 March 2023 The Trustees present Iheir annual report together wrfh the audited financial slalemenls of Ihe-charity for the 1 April 2022 10 31 March 2023. The Annul Tewrt seNes the purposes of both a Tru$lees' report and a dire¢tor$' report under company law. The Trustees confimi Ihal the Anr4Jal re￿1 and linan¢4al slaterr￿nIS of the charitable wmpany compty ￿th the eurrenl slalutory requir￿ents. the requirnnents of the charrtable company's governing document and the kXOVigOnS of the Stemenl ol Recommended Practiee ISORP) applicable lo charities preparing Iheir accounts in accordance wrfh the Fin￿￿la1 Repth'n9 Stsndard ap￿Kable ￿ the UK and Republi¢ of Irelan¢ IFRS102} leffe¢li¥• 1 January 20191. Since Ihe group and Ihe Chanty qualfy as smal under seclTh 383 of Ihe Compantes Act 20(6. Ihe Group slr81egi¢ report required of medium and companie$ under the t¢￿￿S Act 20C6 IslralegiG Report and D￿e￿Or$, Report) Regulations 2013 has been c¥nitled. The group and the Charily also trnje vThler Ihe nam Alber9y UK. ObJectlv•s and actlvS11•s . Policies Ind objectives The Chorilabb Object$ for the thariiy are: 3.1 To raise publ￿ awareness afound allergy and the causes ol anaphylaxi5. 3.2 To produce rdiable infomalion and education in the communrty for the managernenl prevenlion of all allergic reactions, indudiw anaph￿axiS. 3.3 . To Provide 5UPPOrt in the ¢(KrKnvnty to all those affecled by 8ifefgy. coverin9 all manrfeslations ol allergy lo reduce r￿k of serious allergK reactKJn (anaphylaxis). This support extends to bereaved lamlies. 3.4 To promole research into Ihe Gause and care for 811 allw9ic Condit￿nS. including 105e that caus anaphYIa￿s, in order lo improve health aTrJ qUal￿Y of life for people liwng with albprgy and associated diseases. 3.5 To increase the profile of and artvoca￿ for all allerg￿ ecffKlrtk)ns, induding the seri0Lt￿ss ol anaphylaxis. woviding •Jvi¢e and rep￿sentatIOn to government. industry. and otheT organisations. and being a conduit lof informalK)n and research lor a range of expert and paiient stakeholders. 3.6 To tsmpaign lor policy and legisLth've ¢haNJes to improve Ihe lives of aH people living with allergy. including Ih05e who live ￿th the risk of aDaph￿8¥1S. In s$lting Obl￿{￿eS and pkannirvj for adivitses. the Truslees have gven due consKlerntion lo general guidance published by the Charty Commis5￿ reling lo publiG benefrt. indudiNJ the 9ubJance benefil.. running a charrty IP821'. Achlevements and p•rfomianc a. Maln achi•v•ments of the Charity In 2022123 we cont#)tsed lo wod( lowards ow strategic obieclives as $et oul in our Strategy for Chan9e 2020- 2025 plarts. We are ddighled lo share with you Ihe Auergy UK Impad Reporl for 2022-23 $how￿se9 the woth that we have undertaken over the last Ye￿ to ensure we conbnue to prowde support and Servi￿ lo those Iwing with allergic disease ac¥055 the UK. The report is available lo be wewed d￿lIallY on our website via the link below. with a svmmary ol key achievements mentioned hero in this rewt. hltps'.I*￿.al1elgyUk.0rglresOU1CesIa￿ergY.￿k-Impx1-repOrt-2O22-23I p￿e2

The British Alleryy Foundatlon (A Company Ilmlt4d by guafants•) Trnste•s' report (contiTrued} FOT the y•ar ended 31 March 2023 A¢hlgvwnents and p¢rtormanc• l¢ontlnu¢dl Res•arch- Llnd•rntanding Allergy Patient Charter lor Peoplo Liviftg ￿1th Alkryi¢ [￿se3$ "Allergy UK'S research 5s used lo infomi seNices we proNide. public affairs campaigns we lobby on beh811 ol the 81lergic communrty..and the $lre9ic approach of the Charity. Our ieal-wortd ev1(len￿ survey and focus groups in 2021 led lo a collaborat￿n tjehveen patients. careTs. ￿TricianS Alergy UK and Ihe development ol 8 Patient Charter lor People Living with Akrgic Disease. This Charter was launched al Weslminster in May 2022 with the key vision of.. A rjght to a qu81ty $18ndaTd ol care". ftyeveryone hryng rgylhrou9h¢xrt the UK A right lo accurate information edwation." ErnFh74verment ol pat￿nts with allergi¢ condit￿n$ Its vndersland and manage Ihwr ￿￿ditIOn %wth support frcyn inforned heaihcare prolessK)nals A right to equality in sociely- Promolitin of a better awareness #nd urKletslanding of alergy so that people with allergic conditions are not discnminated against in any aspect of thwr daisy Iwes. Thg findings inforrne¢J thè devebpment ol Allergy UK'S k)ng-lerm ¢ampaign which launched in April 2022. The aim of the carnpaign is lo ￿se awareness of the ¢hallenge5 associated wrfh living wtth an alkngy, acr055 the whole spectrum ol alergic condilions. It also seeks to shilt publK perCeptR%￿ on and th& needs ol Ihose who live wilh an allergy. As a part of our campaign, ￿ a￿ ad￿caling lor prThry care lo have specralisl allergy nurses and d￿tilIanS in every Integfate¢J Care Board IICBI. IC8s are nty# resp)nsible foi commi$sionin9 allergy servÈces at a lo¢al l¥vel Iwht¢h are not spe¢iali$t sem￿) ￿K1 Akrgy UK seni CMJI a Freedom cl Information ¢qu&sl to all 42 ICB$ in March 2023. We are Ltsing the results of IhÈ ANer9y UK funded research of a nutsè-led allewy clin￿, published ￿ 2022. 10 support this campavJn,. 01 those Teferred into Ihe semce 90% of heallhcare piofessKJna15 slated that they would have referred Ihe patient into secondary care. had the clinic nol been availle. Incwjenlally. after being seen in the nurse led clt"ni¢. onty 5% of Ihese patients required to be refer￿ onlo to a secondary care service. The project ran belween 2017-20218nd the results were published August 2022 in Clinical and Translational Allergy." hllps'.I1onh'nelibrary.wiley.comldo￿1ulU1O.10o2l¢1E2.l218o showng improved patient pathways ond ¢osl efficienoes. Akngside this, we are rfrvhsrting Ihe evalualN of ￿lergY UK'S Dtelilian Seryice lo gather cuirenl data on Ihe impact this service has made lo famils who have used it. Over 1600 infants have been referred through this ser¥i¢è sin¢e its iwlion in 2015 and many have been seen lo have gone on to r￿eve a diagnosis ol food allergy. PreV￿￿S evalUal￿n hyhliyhled Ihe FM)silive wnpact cl this semce for famlies and support from GPS for Ihe service. Empowering- $upportMig and Infomiing Ihrough our Hèlpllne ¥nd rÈsour¢ès Our Hewline ¢onlinued to prOv￿1e essential infcimatlon and support lor the aler9￿ cornmunily Ihrougholil 2022123 wlh a 12.6% increase in calls fiom Lqst year Many cal￿r5 are an￿Ou$ about Ihw allergies. Of suspecleil allergies and Ihe Helpline has received a kjl ol calls 8bcAJl Ihe ￿￿OI1011a1 impaci of INing with this dis¢g8p. Feedba¢k Irom Ihose who use servi¢es shows us.ihey apprecote Ihe advice and care received as they ollen cannot seem lo a￿e$S other supp)rt. Allergy UK is Ihe allergy chaiity ith in-house Clin￿ experts IN allergy. 180 calls to our Helpline required specialssl support Irom our inthou5e ￿￿rgY Nurses, wrth 48 calls r￿ded advti on eczema provided by ou Allergy Nurses. This ha5 highlight&d a need lo develop thi$ ec2ema serv¢e in 2022123 as a bespoke Se￿ICe. We wish lo thank ¢)ur Pleallh Advisory Board gnd our cb"nical Twstee5 foi Iheir expertise and conslanl support for all cal$ to our Helpline. Page 3

The Brftl$h Allergy Foundatkn (A company limitèd by guarantee Trusl••s' r•port lcontinu￿> For the ye•r •nded 31 March 2023 Achlgv•m•nts aNI l¢ontlnu•dl Our Dietitian serv￿ has supptyted over 1600 chldren in a &￿ar wod where parents Call. often in desperat￿n. as they have been unable to have the¥ conceffls about their chihj's suspected food allergy listened lo or are unab19 to access sc4n8one wilh ihe oxpertise. 320 children ¥￿e supporte<l Ihrough ¢)ur D￿tstian sgrvices this year. and we h￿e this seNKe wil be su51a1na￿e wth cont¥iued grants and sF¥)nsoTship. Over Ihe last year. the youth engagement program h85 invited young people lo participale in act￿118 with Allergy UK to share Ihw"r $lori8s ol liwn9 Wrth altew. false awa￿neSS of alkrgy and gain peer lo peer $upport with an avera9e of 12 10 30 young people gelling involved in the adVit￿$. In August 2022. the young people m¥t face lo face in London whereby they able lo pticipate in lun actiwlie5 and plan the main a¢tiv((y to create a film over the next 6 months. The film will be ccffipleted in Ihe SUmn￿r of 2023. Since the recruitment of 8 part- lime volunleer ￿OrdInat0[ in 2022. the voJunteerir¥J programme has welcome¢J 17 voluntee(s to part￿ipate in a variety of roles from lundraising, event management. lay Tevivw and projed managemonl. Volunteers have made a real impact by supp￿lIng u$ to Implen￿nI a prge¢t manwenl system. ¢oordinate and run an event in Apfil 2023 and lundr8ising at Christmas. Educal6ng- Improving awaweness, kn￿%1•d9•. and Skills kn allwgy Our educalKJnaS resouros Support patients. ¢arer$. and non4Frtialisl heatthcare prolessionals in developing knowledge of alkrgi¢ disease and in 2022r23 we developed many excel￿nt additional resources to provide advice and information foi people INIW vrith allergy. Our pa￿nI pathways digital resource ￿rned al parenls ard carefs who are INing alIe￿y, takes them on a journey through each 5tsge of Iransrtign with useful support tools and lips lo manage th15 often slresslul lime. We also ¢￿￿ed resources lor managing asthma, adrenaline auloinje¢lors. cows milk ￿tergY and house dusl mite. The resources leached both people living with allergy and the healthcare professional supportirvj them. Tr ￿$OUrceS in¢lLth faclsheels, pcJcasls and vide05. In total we is$ued 12 new resources. Our popular masterclass programme for healthca￿ professionals conlinued lo grow in 2022, bringing together primary care pra¢titionets to leam directly from experts irb the filed of allergy. We delNered 7 maslerclasses vAth 1.6￿ registrat￿nS. Our resources are th well received by heallhcare . profession￿8 bilh 1.322 d04vnbads duriny 2022123. Influen¢ing- ¢onne¢ting with k¢y $tak¢hold•rs Our fO￿9rd focus 1$ on wr "Ifs time lo lake alkrgy seriously,. engaging wilh key influencers and stakeholders lo raise awareness of the needs of people living wth aNergy to influence change and equality for all living wilh this Complex disease. In Augu4 2022 we re-contracled a public affan company, conr￿Cl. for a further yow and through this connection we have rnet many mrye MPS and Peers to dts¢uss the needs of the al￿rgIC comrnunÉty. This engagement focus with key decis￿ makers will conlinue into fuluie yeats as a key part of our campaigning, and lo dale has Ènabled us to se¢ure ¥ TrUM￿r of Allergy Champions. We have also work with Connect to SLPPOrt Ihe All-Parly Parli?mentary Group on Allergy Chair. Jon Cfuddas MP. load a Pailkamet)lary back4)ench debat on 8Uergy awareness in Westminsier in May 2023 We have also aitended a Westminster Hall debate on a national lead for allergy and l￿d labeling on menu5. Allergy UK is a part of the Nal)nal Allergy Strategy Gr(KJp. which piovides the Secretariat for the AlkParly- Parliamenlary Group for Anergy. in October 2021 patient repre5entalives deliver￿ a report lo Ihe then Minister loi Cale and Men1 HeaAh, Gillian Keegan MP, whth oullined lh& continued unvmet neèd of allergy seNices across the UK. This meeting has led lo several meetirig5. whKh have been on-g0Tr)g in 2022 anil 2023 with Ihe Departmenl of Health and Sooal ca￿ Long Temi Conditions team. AF￿rgY UK is 8 core represenlalive for pal4enls al these meelings where Ihe NASG are proposing the establi5hrnenl of ￿ expert advisory group lo support a National Allergy Strategy, which inform poly devek)pmenl on areas which impact on INing wilh alleiury. Page 4

The BrIt￿h Aller9y Foundation IA company limbte(I by gu4rnnt•e) Tw$tees' report l¢onllnued) For the year ended 31 Mar¢h 2023 Achiwwnents and p¢rfomath¢• (continued) We very much appreciale Ihe support thal ow Parfi•nentsry AJer9y Cham￿OnS.¢ provklin9. abngside those other MPS and their Officers have expressgj supwt for our campwgn and allended our Parliamentary venl in May 2022 lor the launch ol the Paiftt Charter at)d have supported debates and discussions This work will ¢ont1nue Into 2023 8n(I beyond. wrth dÈcisN)Tr m&kers aeJoss the U lergy UK also Pl￿ a key influe￿Ing role at 8 UK level wth in¥dvemenl in.. the Nat￿n81 Alergy strate￿ Group. the steering group of the Children and Young Peowe's Alergy Nthtslk in Soxland {CYANSI th¢ Patient and PublK V￿Ce partner lor NHS E￿jIan(fS spe￿￿1$ed Commissioning Clinical Reference Group frjr Immunobgy and Allergy Servi represents patient perspecttves when asked by the Medicines ￿ Healt￿re prLhJucts Regulatory Agency IMHRAI and the National Inslilute ol clin￿01 Ex¢elen¢e INICEI a member of Ihe Royal C(Alege of Phys￿l3n$. Improving Qlwiity in Allergy Swvices IIQAS) a¢¢Teditalion $leering group is a patient represenlative in many ol the Brili¥h So¢iety for Alefgy ant1 Clinul Immunology IBSACI) aclivil¢es has regular rneetin9s wilh the Food Slandard5 AgenGy {FSAI and is a wntad lor thè Food SlarKlard5 Scotland {FSSIAllergy UK ako plays a key influencing role 81 a UK levet wrfh invdvemenl in." Al ¥ European and global ￿Ve1 Aleryy UK'$ infiuen¢e 15 n ￿llaboratIOn oiher peer organisalions. Our Chiet Execulivg was voted President of the European Federation of Aller9y and Airw8ys' Ob5eases' Patient OTganisalion5' A530ciation IEFA) in 2021 by our European peer organisaknons. This 1$ a two.year post, as Allergy UK has held a place on the EFA Board for 4 years lo dale. and the CEO stepped down as President ol EFA in April 2023 In addition, Al￿rgY UK held the C¢>Chair posrtion of Ihe European Academy of Allergy and Cknical Immunology Palient Organisation Commitlée until Otlobev 2023, after IhrÈè and a half years supporting gkjbal patient organisalions in this robe. The charity is aFso a member of Gkibal Skin, and Ihe Global Allorgy and Asthm8 Palient Plalfomi IGMPP). Al these collabwalions work to raise awareness ol the issues Ixed. seeking lo influence polKy and sthial changes lo improve equality and qualrfy ol life loi peopte livin9 wilh allergies. b. Fundralslng activities and income generation Allergy UK is registered vhth and has paid Ihe Levy required by the Fundraising Regul8tOT. The Charity is a member of the Institute ol Fundratsing and uxnplies with all required re9tslalh￿9, including ensuring. all procedures Comp￿ wilh General Data Proteclion Regulations, Ihereby protecting the data of all vtho contact the Charity. We are pleased to advise that we have nol receN*d any Compla￿1$ felatiro lo fundraising during this year. One of our key goal$ is to $lr&ngth$n our income generation capability lo $aleguaftl the long4emt future of the Charrty. Currenlty every"£1 we raise prowdes 53 pence lo deIr￿ our seryices and our objeclive is to incfeasè this contribulion. but this ss reliant on Un￿St11Cted income and grants to supporl core seryr¢es. We have four prinripal revenue streams. including i[￿)n￿ receiv￿ via Ihe charity's tradin9 subsidiary Allergy Research Limited. Communlty Fundraisln9: In 2022 we recruited a He&1 of Fundfaising and a Senior Fundraising Officer. both ol whorn have be9un lo make a real impact (x) managing and developing plans lor oiir lundraising income stream5. This has been essenlk71 lo womding support lor those lndN￿uals and compan￿5 who ale generously commilled to donating and raisin9 funds to for our chwity and for alkryic disease. Page 5

Thè Brillsh Allèrgy Foundation {A company limited by guaTante• T￿￿t•$' r8POrt Icontlnu•d For the year wmlod 31 March 2023 A¢hl¢v•menls and p¢rlormance Icontinuedl Judith's Wish was the Christmas 2022 fvndraisiThJ ¢arryaign. The carnpaign's key obiethes were lo e￿(￿le people abovt the dangers of severe I(￿ allerg￿$. h￿h1￿jhl the need to improve the labellrrfJ of food arKI drink pr<xlucls 8nd to rai$e much-needed fvnding for Ameryy UK. Judrth's Wish was disseminated di9ilally to 24.000 people Iwhose lives have been affected by allergies) a¢r¢)ss Ihe UK"in November 2022. A lurlhei 3.000 copies of the ¢8mpaign leallet were distrdxrted to the public in ErwJl#nd. whilst an 8dtJitional 1.000 copigs were issued In South Wales. 11 was a greal year lor Commun-ty Fundraksing. ￿1h Allergy VK being lortunale enough lo secure Htgh Slieet p￿SenCe for colle¢tK)ns. Donations were made and over 1.000 cops of OLtr Judrth's Wish campaign 'leaflels di51ribuled. To dale. Judrth's Wish has received donatv)ns exceeding our largel by over 110h. We were ' also fortunate to receive thè suppori of fve bxal businessès who 9av6 in kind donaiions for Ihe campaign In 2023r24, our Chris¢ma$ Carnpaign awn5 to grtr•i Trts reach by a further 10% and in¢rease it$ Ihe amounl of mon raised by an addrt￿l 20%. London Krbights continues lo offer their orwJoirwJ support lo Ihe cause and have hekl two raffles and a hockey lournamenl in 2022, in aJ of Ruben'$ memory. AII¢F9y UK wcwld h.ke to extend our mosl gncere and heartfgtt thanks lo the Bousquet family. The London Knightz al Ihose WI￿ have so generously supporled u$ over the past yew. Allergy UK is exlremely grateful lo all of OUT SUPWters and those who have donated through fundraising, donating to appeals, kgacies and olher ways. as dew'le the ¢￿tInued difficullies from the economic impact our supporters did increase individual gsving don8tions during 2022, en)ling us lo dehver Serv￿￿$ for 811 li￿n9 Wth allergy in lh9 UK. wit￿Ul Ihesg d￿011￿$ and $upwt our wor woukl nol be possible. Trust Fundraising: It remwns very chalengiThJ to SKUfe fuThJs deSP￿e c(¥￿actIng an extemal ccffipany to ctimplÈtè and submrt bids. H¢)wevei. we woukt like lo thank Piking1¢)n Trust fof their ¢OnlinL￿d svpport with granls. receiving £5.0￿ ￿lch we very much ¥ppreGiale. Other grants received were Novartt5 Ph3[maceut￿￿ls for £6.195 50 that Allergy UK wertr able lo raise awareness of Chronic Sponlanecws Urticarra. a corYJrtKJn olten mislaken lor all8￿Y as il presen1$ lik¢ an alleigy. No other org8nisation in the UK supports this condition. We also thank Global skin for $2.400 CAD lo raise awareness ol eczema on World Eczema Day. Nutrica £4,680 to enable Allergy UK to be represenl¢d al the British Sooely of Allergy & Clinvl Immun¢Sogy. Aimmune £5.529 for resoU￿eS to support people living wilh the psycholc43ical impacl of f(y)d allergy. pfizer £9.466 to support both Heallhcaie prole$sionals and people wlh skin al￿rgY W￿h resources. and SaTh)fi £77.853 for a youth en9agemenl project. parent and carer 34lPPOrt and skin resour¢e Corporat• Partnershlps and Sponsorshlp: Most sponsorships re¢eNed Ir¢)m ¢orporale partners. and we woukl like lo express our thanks and grdlitvde to all ¢ompanies who COnt￿lUe lo support Allergy UK. year on year as their support is essential lo our sustainability. wthelher Ihis be through a granl, or sponsorship of pi(4ecls Ihrwgh our tradiNJ subsidiary, Alergy Research Lmmited. In 2022 we had 16 estatAished corporate partners. which has enabled Allergy ill< lo cnnlinuè lo delNer some key services. such as our Dietrtian SenpiGe. provtde Iree MaslercEa55es for heallhcare profess￿nals. and devek>p . iesources on alkng￿ disease. Corporate parfnei support has also enabled us Its launch our Youth Engagement Progr￿￿¢ in 2022. Those who supported proiects and adivilEs that look ￿ace in 2022 are also lisled in our Impact Report. and we wish io thank Abbotl, Abbw, Aj'mmune. ALK. +ecohydra. Nut{￿ba. Phzei. Poli. Robert Th￿a$. Sa￿11. Sealy. Novart15, Naroo. Endors?TheNts and Li¢ensing: Our Ifading $ubswJiary Alergy Research Limiled provide5 endorsements lor products whtch may provide supP￿t lor lh& symptoms expèri8n¢ed by peop￿ livng ￿th allergy. The company donatès all profits lo Allergy UK each year enabliny Ihe charity lo utilise these unreslricled funds lor (wèralional and olher costs. Page 6

The Briti$h Allergy Foundation {A company limlt•d by guarantee) Tw$tees' r•port (¢ontinued) For the year ended 31 Mar¢h 2023 A¢hlev¢m•nts and porformance Icontlnv•dl All donated income from the trading subsid1￿Y dKedty finances Ihe charitrfs expenditure on operational adTrvilies and slaffing resources. OperatKnal expenolrtU￿ pro¥￿e$ a Pelpline.. Ihe funding ol a communications team lo promole awareness of allergK diseases," Ihe emF4oym¢nl of Ihree al￿rgY nurses and a dielilian to support the helpline and provide subj'ecl maitw exptrrtise on aHer9y and irnmunolcgy", a team supwting Ihe Irading aclivilies an(J inv¢fvement wrth other organisations with the s￿￿1181 fcrtus on areas of allerg￿ disease. All surpluses will be Used lo finance fulure chantable eypeDdrtUfe. either for ongoing ￿tIl￿1es. or one-off proie¢l$. The trading Subsidiary provides the Charity's prncpal fvnding source and conkn.nued lo p¢rfofm well despite the drff¢ull global economre cortditions. Both rt5 major 8¢trthlies (cperation of endorsement programmes and working with corporate partners) exceeLled expec1atio￿ for the year. Ihe budget for which had remained conservalive when considering the economic lorefasis. Our tradiro subshyiary activities are all aimed lo be of benefit towards achievbng the Charitl$ atsns to WOVKle support lor those Imng with alLergy and ra￿e awareness of allergic d15ease. Cash flow has been ck)$ety moimlored throughoul the year and all ouffiows are planned and well within the Charills le￿￿1¢¢s. H￿￿ever, in 2023124 we whl be revie4Wiry hcw much of OUT reseNes we hold in fixed lerni accounts lo ensuTe cash 11(w is not affected. The a¢tiviti¢s carned out by the Charit￿$ subsidiary, Allergy Researth Lwnrted, require higher ￿${S compared lo a charity which ortly seeks public donations. endorsement scheme independently lesls applicants. products using speaalisl laboratories al commensurate fees. Allergy Research Limited activities Inv￿ delivering pfoj$¢l$, wh￿h are $ypp(xled by sponsorship from our ¢orp(wate partners. These piojecls are aimed al increasing pubfic and heaAhcare professional knovAedge and awareness ol allergy issuès. The endorsement schemes and proje¢ls incuf ￿$1$ to enable the achievemenl of oulwnes and many of them are now delivered through digrtal solulions lor which the Charity ukn"lises third party provJer5. These cosis are Govered using donated ¢onlribulKJrn5 from ¢)ur corKKJrale partngrs an(1 any surplus funds d•s￿nated lor Ihis puip05e. Tho majorily ol the Charills ￿COrne is generated. the subs•Jiary. by these two ￿eans. Financial reviow a. Golng concwn After making appropriate enquiwie5. the Tntslees have a reasonable expectation that the Charrty h8$ adeqvale resources lo continue in operational exislerKe lor the fo￿Seeab￿ fulure. For Ihis reason. they conlinue lo adopt Ihe going con¢em basis in preparing the financial Stale￿￿nts. Further details regarding the adoplion ol the going concern basis Can ￿ found in Ihe a¢countiig wlKie$. b. Reserve5 policy The Bowd of Tfuslees rev￿e￿ the reseryes polKy in accordance with thg ¢lK3ritls Strateg￿ p￿nning, operational decisions. bJd9eling and risk managwnenl pcocesses. At every Board meeting. the Truslees see the movemenl in reserves and, therefore, ale aware ol the levd of iesoNe$ held by the charity. In addition, Iho reserves position is usually f0m1al￿ rewewed {W￿e a year in February and September. Financial risk management for Ihe 9104p ind￿leS ensuring thal thwe is Suff￿lent conlingency reseive lo enable the group lo ￿Spond to an unlore5ee0 event or emergerw. The Trustees provide the CEO wrth Ihe authonty lo make financial decisions relating lo operalional need. woviding there are three lo four months conlingeney reseNes available. This is rewsiled every 6 monlhs lo ensuce good financial praclKe. 11 i8 Allergy UK'S policy Ihat any financial decision (hal woukl resull in reducin9 the conknryncy reseives lo urKler lour month5 of the charity's operational ¢o$ls woukl have lo be es¢alaled lo the Board ol Tru$lees for a d￿lSIon. Page 7

Th• British Allelgy Foundatlon (A Company limited by guarant¢#) Trn$tees' report {¢ontlnu8d) Fof the y•ar frnded 31 March 2023 The charity receives a sleady income stream from it$ twling sthTrdiary. and it Trs Mn$•Jered highly unlikely that this would ¢ease immediatety. It is assumed Ihal. foT the purpose 015etti￿ the reserves ￿¥trI, income musl be sel at a level wh￿ti is equal lo or exceeds expenw. There could. h¢￿Ver. be a sleady crf sudden redU¢th￿ in in¢ome arising from events ouiside of Allerw UK'$ conlrol and sUlf￿lent res￿e$ should Iherefore be held lo cover a stressed drop In income over a period of Six monlhs. This would 9ivg managemenl line lo lake action lo headcounU¢osts to match the kn¥er levels of inccffitr. The average mcnlhty inc(xne foi the grrAP in 2022rd3 w88 £152.070 ond 15 ￿rrenIty £130.000 (February 20231, which excludes acy incorne. A stressed redud¥)n rate of 10% per month has been applied lo cakulating the reserve r￿uireMent. The Trustees have set a minimum reseNes requirement at Ihwg months of cuirenl average income1£390.0001 lo cover a pclential 10% slressed reduction in income over a SiX•month period. The balan￿ on ihe cc)tingency re5er¥e al 31 Mar¢h 2023 wa$ £466.220. The ￿ting￿nCY reserye must be deposrt. a¢o)unts at a mi¥ of temi$ arml maturity date$. bul not exceeding 12 M￿lh$. to the funds lo be ￿ceSSed when required. The Trusle$s eypts¢t manapmenl lo maintain a reseNe ¢ushion * least equ￿ to the four-month minimum and musl be immedialety of any events or expendituie that mpjht Cause the reseNes lo fall below that level. The charity wdl aklays seek lo ulilise funds èbove this levd to (￿rther ils oWive$. The dwgnaled reseNes on the balance sheet ¢￿t￿l￿8 to drflerentiate free funds from those invested in fixed as$els or commiited lo ¢ther spe¢ih'¢ projects. However. des￿nated reseNes represent free reserves that have been allocated for a speafic use by Ihe Boaid and can be reallccated at thèir discretion. This difterenliales them Irom reslricle(I resew that have been r￿1ved for a $pecthc purpose and can On￿ be used lo delivef thal objeclive. c. Finan¢l•l $tatèm•nts The financial sL7lements kn Ihe yew end for 2022r23 an N￿ome of £1,524.848 and expenditure of £1.673.217. d¢¢reasiNJ ro￿1ve$ by £148.369. The chartys income was below bJd9el duè to sèvèrnl factors. Granl In¢LNY was over £27K be¥DW budgel Individual giving nearty £7K_ 11 was initially the￿ght Ihat ts campaKJn senl (Mjt by social media would raise awareness and increase direct debts by a hwjher level. ' AddrtKJnal grant IiKome was secured. though wth Ihanks lo Garf￿d Weston. Pilkington Trust arKI Novart15. bul this was wdl below bud9et foTecasl despittr many hKJh-qualty applications lo Trusts and FoundatKJns. Recorded Gfanl funding in 2022 is higher. with some Teceipls in earty 2022 relating to projects taking place in 202213. On a ptssitive noie, ¢o$ls were well conlrcAled the year and overheads re over £185,000 below budgel albeit this 15 mainty 5awng5 on va¢ant posts. The liading subsidkgry. AWer9y Research L¥niled {ARLI, profft 8t year eThJ was £799.908. The forecasling had been very conservative due lo the unkncmn impa¢1 ol the pandemic and giobd economy. These risks and challenges wntinuo and therefore the budgel foieca51ed for 2023124 has also ￿rned lo be GonseNative. The new credit conlrol process has alreaty shffivn good results wrth debts over 3 months old being mduced. This process conlinues and ARL Debtors had been redu￿ lojusl over £75K in earty September. d. Prlncipal rlsks and unc?rtaintie5 A slralegic risk register is maintained conlinutyjsly and feported al every charity and trading subsidiary board meetin9 and more often il needed, wlh planned mrtrg8tKm adNrties and progress on these. The impacl Irom post Covid-19 and global econ0n1￿ challenges carried forwaid into 2022123. Page 8

Th• British Allergy Foundation IA company limil¢d by guaranlee) Trustees. report Icontlnued Foi the year ended 31 Mavch 2023 E¢ohomlc ¢llmats and Cost of livlng The economic dimate and cost of11vi￿ increases we ¢ontinuin9 lo affect everyorE. inclLJing ¢harities. We are privileged lo have many fantast￿ SUpp￿er$ who donale and Taise lund5 for our cause. bul we have seen Some cancellalions of regular dire¢l detH"ts. 11 is vèry difficult lo ratsè funds for al￿rgY through grants Irom Tiusts and Foundations, mainly we beI￿ve becavse the impact of liwng with al￿rgY is slill not uThYerslood. In 2022rd3 we have applied for over £500k of grants bui have been unsu¢eesslul except for two Sm￿1 grants. We would like lo offer our 8ppre¢ialion lo Garfkl west￿ and Ihe Pilkinglon Trust Founts1￿ who have both provided small grants lo our charty during this hnancial perK>d. We have also expeiienced increases in the costs of g￿d$ and services. In todals environment al charities. musl have IT systems and prograrYwrn$ io be able lo function tn Ihe modern WOrk￿aCe. corr4)ty with required legislalion and ensure the safety of data. The costs in this fiekl have been increasing considerably. Alongside Ihis. salaries have increased auoss many sectors and recnjrtmenl during 2022123 was extremely expensive and lime (￿SuM1r￿J, due lo reGruitment agency cost$ and employ8e expeclalions on salariès. BAF has aK¥ays benchmarked salaries wdl. bul a small charity lo be a>le lo fecruil experienced staff we have had lo raise salary levels. This has an onwng on finan¢e$ at a th.n￿ whon it is even rr￿e dilfi¢ult lo raise funds Ihrou9h usual lundraising and ti•Jing acliwiies. ARL ha5 seen a change in the lype of business being conlraded. is as 8 direct result of e￿nOMiC pressures faceol by companies WI￿ seek our endorsemenl seNtes. We have also found Ihal many ol our orpoiale partners. who support us Ihfough grants and sponsorship, have reduced Ihe amount of funding available. Many ol these corroanie5 have also changed their funding timeframes and in January 2023 this did raise a risk ¢)n ¢ashflow for a very $hort pericml. Our main ¢ontin9ency fund5 awe usually held in a 0￿-year fixed term account so we had funds bul could not access Ihem ￿mediatety. We review the amount held in fixed ler accounls every year and for 202W24 and Ihis cashflow query will inlom decish)n5 we make for the future year. Finance and Audll We faced a huge Challenge in 2022 as the re¢wilment of a F￿ancts Business Manager wilh Ihe Tighl skills 8nd experience lor Ihe salary we coukl offer took nearty a year. In that per￿1. we ¢Mtracted an exlemal finance agency, Oculus. who were very supportNe and prowded t￿ assucance of mainta.ning required financial management for almost len months. This was exlremety c0511y, but unavcidable. )d meant that a lol offinance lask$ be¢8m& Ihe retr￿1 of the CEO Operalions Director. As an addilional challenge. we had planned lo ¢hanye our finan¢e syslem Irom 1￿ April 2022 and Ihe mov¢ from SAGE to XERO was inleresling. We are pleased lo advTse that 311 challenges werè ¢)veicome. bul the complexty of mtsving from one system to another cne at a time vthen we had appointed new auditors. Kreslon Reeves were incredibty supportive, and we would l.ke to thank our audrtOf5 for Ihetr paI￿n¢t whilst they undertook a 'deep dive. of the charity and the trading subsidiary duriNJ the audil process. The challenges outlined did dday the fi'nal audrt being signed off by Trustees and Directors. which ioc p In Novembei 2022 when usualty this lakes place in Seplember 2022. H(Mever. we slill submitted all required dcturrnlation lo the Charity Commission and Companies House. and Office ol the Sccllish Charily Regulator. on time. We appointed lo the Finance Business Managef post in Novembw 2022 and ihe XERO system has been in place for a whole financial year. enabling the aud for 202212310 rrnre smoothty. Re¢ruitment Challeng The posl-pandemic period has been a challenge as we l￿d styne kng-temi staff made deci6ion6 to felire or leave. so we had a need to recnjil staff to key posts in 2022. We were succe551ul in covering posts for ¢)ur fundraising, communications, public aNairs, helpline. project Management. youih and volunteer enga9emenl, food safely awarenes$ and finaw. Howevef. the timeframes recruitin9 some of these p05t$ were considerable. This impacted on agency costs for recruilmenl as well as contracting external consultants lo cover key roles. such as finance. 11 also meant that a bt of addilK)nal tasks fell lo thè CEO and Operalions Director lo ensuie required a¢tNit*s moved forward. We have also had a Coup￿ of these posts become vacant again and are ¢urrenlly not recruiting for these posls as we take a risk assessment 8pprtsa¢h to the conlinued uncertainly ol income during 2023124. Paje 9

The Brltlsh Allergy Foundatlon IA company limited by guarnnt••) Trustees. r•port Icontlnuedl For the year ended 31 March 2023 Albeit inilialty we had lourKI the relum lo office working and hybrKI workin9 not have too m8ny challen9es, we lound that onknafding crf new staff Into a team woJkn"n9 fomMI was GhallervJu)g post£ovid, tthere many if not 811 had worked remotety fry a bng peri(xl ol time arKI found re•connecling lo an office enwronment quite diff￿￿11. We have worked hard in 2022r23 lo support slaff embedding into Ihe charity and trading sub￿dIary. and provided staff suNeys for feedba¢k. as well as addrtional supkvl through welléing acts'vities. W$ have inlrojuced hybrid working arrangements, whKh has created conneclNe challenges of its own lor cross-leam development and awareness of olhers, role$ responsiblrties. We held an Away Day for all slaff in July 2022, facililaled by an external coaching eyrt with the aim to bring staff tcgelher to share an understanding of each olherfs areas ofwiyk and expertise, a conneciion wilh Ihe ¢hariVs values and objectives, and for Ihe teams lo gel to kn¢y•V ea¢h olher more. In J•nu¥y 2023 w¢ he￿ on alkday act¢vity where teams shared their experiences and expertise with each other. All managers mel off-site on a second day to discuss the oulcome5 of a Belbin le￿ exercise, and lo devekp their shared appro¥h to delweryof key obiedives for the year ahead. L•a$fr and Offic• Mov• Another unforeseen challenge has been our landknd asking us to Su￿￿￿er our lease n￿re th￿ five years early due lo their desire lo change the LK%e ol the buihjing, whi¢h Post-pandeM￿ have lots ol vacanl Off￿ space. These discussions comMer￿ed in earty 2022 and are onty just being finalised, with an offte move by the end of June 2023. There have been negolialions lo try to cover unforeseen costs but Ihere are many aspeds lo eonsider when Moving a company address and this ha$ 8dded lo other thallenges and change management for Ihe charily. We have engaged staff in all aspects oflhe move. induding a Slaff suNey lo ascertain Ihtsughis on off￿e spa¢9. 10 try lo reduce the impact major ¢hangtr can have on emp￿Ye65. We havg enSUfed Ihg ngw premises are In a locatJn which is easEr lo travel lo a MaJ￿lY of staff. Successlon Planning for a neY• CEO Our CEO advised the Trustees tjrectors in 2022 that lo lalth and personal reason$, they were lookir￿ lo slep down after eight years in the role. The CEO provided an exlended notice pencAI wth a leaving dale ol 31$1 July 2023. v4hich has provhled the charity and tradsng sUbS￿lary time lo devebp a succession plan. The Trustees would like lo thank the CEO for their commilmenl lo the charity, and also thank Ihe Operalions Director, who is stepping in as interim CEO unlil a new CEO is iecrviled. Recruilmenl commenced in the lirsl quarter ol this fin8n¢ial year arKI Twstees hope to make an anrthncemenl of Ihe new incoming CEO in the near lulure.11 is a Ghallenge when any employee leaves. bul the CEO has many responsibilities lo handover bolh internally and exteinalty. It is also a change for Ihe or9anisalion to adapt to, but Trustees are ￿rtain a new CEO will be able to build upon the Chanty's successfvl a¢hvemenls when led by Ihe ovlgoH19 CEO and ensure the ¢harily cor)linues lo provbde the best possi￿e support and seNces lor the allergic cOmw￿nrtY into Ihe future. Sustained income generation The principal financial risks laced by the Charity l in the perf¢rri￿ of the Irading subsidiary in delivering the expected levets ol profrt as the charity remains reliant on the trading subsJiary donalK)n lor a maiorily of ils income lo cover ¢haritable ¢osls. Alongside the ri$ks ol r¢du¢ed donations, inabilily lo secure grant fUndl￿d 8ndltsr a redu¢lion in corporate p8rlneT trngagemenl wilh our piqeds, we also have delays to new Iraining schemes we had hope lo launch in 2022123 due to recrurtmenl chalknges The key ski115 required lo deliver this ITaining a￿ being considered and we are hopefvl that the IrainiThJ wll be launched by the end 012023124. Our 3-to-5-year f0￿Cast$ highlT9hl the need for i￿￿ased slreams to W0v￿e slabilily lor the Chauty and a551sI us in avoiding a repeal ol Ihe ne￿ lo rnaior restructure slaifing levels. Our Irading subsidiary is developing a marketing plan with ideas for income generat￿n and the charity's expenditure is being c105ely monil¢xed. Finanaal fofec3sls suggesl Ihal the Charity remains able lo fvnd op¢raling costs over the ntrxt few years. however. this remain5 an area ol coThlinuou5 challenge lor the Charity, especially rf Il w15hes lo achieve 115 fuluTe slralegi¢ objectives. The inveslmenl in diversifying Ihe Chariws income streans should reduce the polential impad of an individual slream being adversety affected but this is in a ¢limale of resource chalerKJes for many in the IhiTd seGlor, and the currenl impact and legacy of CovKI-19 means this land5rape will continue to remain demanding. Page 10

The British Alleryy Foundatlon IA c¢mpany limllad by guaranttsl Tru$tee$' r•port {continuedl For th• year end•d 31 March 2023 These financial risks a￿ mOnrt0￿ closety by the Chf Exe¢ulr¥e and Finance Busingss M•ager on a daity basis.'and Ihè Boartj are wovided with r8gular financi￿ updates and forecasts lo enable them lo assess the Charilvs financial Fosthon. Thi5 is a proper ￿neCtI)n of the use of desrgnaledfunds and the paymenl ol 11a￿.1rt•e5 included on the balance sheet 8131 March 2023. The cash resources have been placed on deposits ranging from instsnt access to 12- months fixed- term. in a mannef thal pro¥￿e$ for the funds lo be avaikble sh¢)ukl they be required. In Ihis way we seek lo maximise the interest earned from prudent inveslmenls while mainlaining the 8¢¢essibility of these resources. Slw¢tur•. goveman¢¢ and manag•m•nt Constllution The ¢)fganisation is 8 ¢lwitable ¢ompany f#nited by ouarantee. incorp￿ted in Augusl 2002 Iwng been first regislered as an unirscorwaied charrty in 1991. The cornpany %wa5 estlished undgr. a Memorandum of Assoctalion which sial¢$ Ihe obiects and p￿￿er$ of the Charilab￿ company and is govemed vndei ils Articles of Assoeialion. In addilH)n lo ihe merrKlr￿dum and ArtKles ol AssotsatK•n Ihe charily also ¢)perales under the Gode of Gocd Govemance approvejj by the Nalional Cound of Volunw OTganI5al￿N￿ aThJ Charity ConNnission. b. Methods of appointhnt or eleclion ofTwste•s A maximum of 12 Trustees can be appoin￿ there art currenlty len on the Board. as ol June 2023. The Trustees meel at least fouf tines a year at board meetings, with an Annual General MeetiThJ usually held in September. However. in 2022 the Annual General Meeling was held in November. This was b￿aUse of the final audit reports being slightly delayed. During 2022 mosl meètings were ad4led lo a hybrhl of in-pefsorb and on- line, as peimilled under Article 47 of our govern+ng document.. The Board ol TNstee$ is respon&ble lor the strategic (Jirection of the Charty and its policy. The Chief Executivè ICEOI. and appropriate members of the Execulive team, allend the Board meebngs as reqUI￿d bul have no voting righls. The diredors ol th8 company are also charty Truslees for the purposes of charily18w and setve lor 8 peri¢)d of three years but may be re-elected lor further periods ol Ihree years. w) to a 1¢>yeai p6riod. OurTruslee James Redding stepped down In September 2022 afler serving seven years on the Board. The Board woul¢J like lo say a huge thank- you lo lor his c<rnrtment and ¢onlnl)uI￿n over Ihis temi. We also wel¢omed Peter Frampton as a new truslee ￿th HR ConsuAan¢y expertise. who was appointtsd in September 2022, and fv40 further Trustees who It￿ned in November 2022. Or. Stephanie Kayode is an adult all¢rgy Gonsullanl al Gu￿S Hospital. which is the largest adutt al￿rgY dePartn￿nI in the UK and is inlern8lionally accredited, and Elr£thlh Wrthers, a policy. aiid publJ"r affars professKJnal experi&ncéd in supporting the voluntary and pubbc sector and is based in Wa￿. The Trustees have the power lo appoint any p8rson lo be a Truslee who may have a r￿Ul￿ed skillsel or expertise. By Ihe nature ol Ihe work Ihal the charty tsrties oul. medical and business knowledge is tequired on the Board ol Truslees. and this Is well represenled on Ihe present boar Truslees regularfy rewew the skills wlhin the Board against a desired lisl o15kills. and this informed recruilmenl .01 Tfuslees which took place during 2022 and 2023. The skills and expeflise ol the Trustees are used approprialety lo steer the charity and lo support Ihe CEO as and when requi¥ed. We have been prmleged lo havè such nèw txperlise on the 8oard ol Trustees, and dufin9 2023r24 recruilmenl Is continuing. In September 2023 three of the Trustees will have completed the (ull 10 years permlled and therefoie the Board is fully piepared lor suslaiThabilly ol ihe g0Vem￿Ce of Ihe charily. Among 11?e many excellenl applulions fece¢ved. the charilV5 Iraling subsidiary, Aller9y Research Limiled ha5 also be¢n able lo re¢ruil-a new Dire¢tty, Deborah Dixon, who joined the ARL Board in November 2022. Deborah brings Drre¢tor level experience in medral he811h pilrshing and ch8rity seclor execulive roles. Pa3e11

The B Titlsh Alleryy Foundation IA company Ilmlted by guarant¢81 Trustees. r¢port Icontinuedl Forth• year ended 31 March 2023 Stru¢tyr¢. gD¥efflance and managem•nl (continu￿) . Organlsatronal stru¢lui and dKIsioN￿kiny poli¢l•s Allwgy UK has a Chief Exe¢ulive ICEOI who supports the Board in delNering the organisal)n's slfalegic objeclives. The CEO has delegaled powers of responsibility for the resource5 01 the Charily and directs the day- to-day operalions of Allergy UK. In February 2023, CEO lor last eKJht years. Carta Jones. thised of their inlenlion lo resign with Ihe las1 working day Of31￿ JU￿ 2023. As CEO she also acted as the Cunpany Secretary lo the Charity and was a Director ol the trading company bul in the intwim peric¥J whilst the charity recrurts a CEO, the Board of Truslees and Board of ARL have made interim deJ"sm￿S whereby Ihe Company Se¢relary r¥sponsibililies are liansferfed lo thè Finance Business Manager. Also. as there are lour ARL Diredors remaining then this role was not to be replaced al this lime. The cuirenl oPeral￿nS Director h8s lèken on the ￿SponSibl1111eS of inlerim CEO during the rKruitmenl of a new CEO. Reciuilment look pla￿ during March to May 2023 and Ihe Board wll be announcing the successful candidale in the near fulure. The Board would like lo thank the oulgoirrfJ CEO for her¢￿tributiOn to the yrtr•rth atvJ.devekJpment ofthè charity over the last eJht yeats. The Execulive team, whi¢h includes an Operations Director. a Finance Business Man39er and a Head of Clin￿al, proV￿e subjed malter expertise and support the CEO in diie¢ling and delivering the operations ol thè ¢harily and trading subsidiary. The Executive leam oversees the OperalKJnal ManBgemenl leam who are responsible loi the delivery of seryKe area activities focused on a¢hving oJr obieclNes through clinical. communications. endocsements, fundraising and helpline. We also have team members with expe￿.$¥ in project managemenl and d818 rnanagemenl. suppoth.ng the charily wrth ¢oordinatitvJ projects supported Ihrough grants and sptsnsorship and Ihe devdopmenl of our cuslcrfner reL7t￿nship managemenl system and dala management. We have a Senior HR and Facilrties Officer to Pfovide pers(￿ne1, heamh and safety and welkbein9 fundions. Payroll and IT supp(M1 is OLrtsourced. d. Poli¢S0$ adopted for the Inductlon and training of Trustees New Tiuslees are provided with a reu￿lment pack which Provides detaAed inlormion on Ihe woth of the Ch8rity, Ihe Memorandum and ArI￿S of Assctialton. Ihe Charity Good Govemance Code, which Sets the principles and Tecommendeij prac1￿e good govemance. Iruslee job iJes¢Jiplion and fesponst)ilil¢es and the last published accounts. An indUd￿n peiiod is arranged lor new Tiuslees lo farniliari5e themsdves with the chanvs work, by ￿MIng lo the off¢e and meeting all the staff catrwny oul the vaiious acts"vil￿S of the Charily, and Ihe ￿centlY appoinled Trustees visiled Planwell Hovse in May 2023. o, Pay policy for key management personnel The Trustees consider the Board of Trustees and the Ch￿1 Executive 8s key management pwsonnel of 1he Charity. No rem¢Jneralion was paid lo Ihe Trustees in Ihe year except for relevant expen$e$. The pay ol the Ch￿.1￿5 Ch￿1 Executwe is aMuah¥ by the Board of Trustees and benchmarked with charilies ol simiL4r size. The Board ackno￿ thal the Chief Execulive's pay sn line wth benchmafk po$itkJn and awarded an irKrea5e lo rellecl thi& l. S•lary remunèration for staff All salaries are benchmarked and reviewed each In May 2023 Ihe Trustee5 received a proposal from the Executive team vthiGh was dbsws$ed and in Jyn& 2023 approved a pay increase.of 3%" lor employees. back dated to April 1st 2023. wth some adjuslmenls depending on length ol se￿l¢e under one year. There were also two posts wh￿h recewe11 incfeased salars due to benchmarkirKJ and performance. Page 12

The Brltlsh Allergy Foundatlon IA company Ilmlted by guafantee) Tru$tees' report l¢¢)ntlnuedl For the year ended 31 hlar¢h 2023 Stru¢tur•, gii¥ornan¢¢ and managwnt lcontinuedl 8. All•rgy UK $tAff tralnlng All slaff complole mandalw Iraining for Complian￿ with saf8WatdirYJ"and heaNh and safety legislalion. Thi5 includes First Alder. and Fire Marshal Ifaining. In addition. our clinThl team deliver in.house Iraining for 811 Stall on allergic disease. to take au staff th￿ugh a joumey ol ur¥Jerstanding on the breadth of allergy. what (( is and how the immune s￿lem'S immunoglobulin E is influen¢ing allergic rexlions. Thts inthouse training ¢gvers atopic eczema, allergic rhinili8. allergbc asthma. locrfj allergy. eye attgrgy and ￿phylax1$ and other additional e(lucat￿n identified. In 2022 all staff compleled themandalory on4ine tra￿ry, vthith i￿lUded health and safety. fire safety awareness, Equality & Diversily. safe-guarding. Cyber-se¢ur￿y. resiltence and line management Irayling. Senior staff. such as managers. also compleled stress ￿areneSS. mental heallh awareness. confli¢t managemenl, ¢ommunicalion $kills, un¢onscious bias. heallh and welkbeiny. and a leadership and management Course. Two staff volunteered in 2022 to become Mental Health Aiders and atiended couTses to develop this inlemal supporl lor the wider leam if required by individual slaff. However. both slaff have $in¢e and lurther training has been soughl lof the Sen￿r Human Resource Officer. Individual slafl also have an annual appraTrsal. wfh regular One-tr￿one$ wrth theii line managers And identified liaining needs included in personal devebjpmenl plan$ to ensure the ch8rtty and its IradiThJ sub>'diary are supported by skilled ar￿ experienced team members. h. Presldent and Vlce41resSdenl Our President. Professor P. H(￿arth is.a lounder Mem1￿ of Charity. He was a Professor ofAllersy Ob)d Respirat¢)ry M￿l¢lne and Hontyary Consuhant Phys￿l3n ?￿h7n ￿ed￿lne al the University of Soulhamplon 8nd an internationally known expert who ha$ been involve(l in supporting the allergic communily throughout hL areers, inGluding Ihrough his roles a5 a prevmxjs Trustee arKS Ambassadtsr for Allergy UK. We are exlremety gratef¢Jl for his supp￿1 ovef the last lthe decades. Currenlly we have no w￿e-PresIdent. Plans for future periods During the next 12 m¢y)th5 we wll Confinue wtyking on the *"e¢tives wtlined in our ¢urrenlslralegy 2020-2025 wlh a sustained kKus on". Conlinue(I monitoring of the economic sitU8lK)n the effect this has on the Charitls income slreams and other acliwb.es Empowemienl of Ihe v￿ce ol the allergic communty through advrtacy and our'lt's lime to take allergy sefiousII carnpaign and other publ￿ reL41K￿s activities across the UK Expanding our supporter bases and ensuring we prc¥nole programmes that have a signrfKant imp8¢1 on Ihe quality ol life ol.the allergi¢ community Broadening Ihe work Ihal we we th.ng wilh UK companies. as we Continue lo diversily our kicc¥ne generation aclivilies through fundfaisng and our Irading 511b5Kliary activiliÈs Exploring new and innovatNe revenue-generaling opportunities Continue developing our volunteer and youth engagement programmes In addilKJli, we wll be welcc¥ning oui nv•V CEO and they will begÉn lo consKler the objectives for our 2025. 2030 strategy. P8ge 13

The 8ritish Allergy Foundation IA company Ilmited by guarantee) Tw$t¢es' r•port (continu￿) For tho year •nd•d 31 March 2023 Stattm•nt ol Tiust¢es' responslbllftles The Trustees {whts are also lh¢ director5 01 the Cha￿Y lor the purposes of company lawl are responsiblo for preparin9 the Trustees, report and the financial staiements in accordaft¢e wlh applicable law aTrJ Unit Kingdom Ac¢ouftting Standards IUnile¢l lfj"ngdtyn GenW￿tyAttePted A¢ccwnling Practice). c￿panY law requires the Tn￿lee$ lo prepare finarKial $talemenl$ lor each finan¢ial . Under ¢Dmpany law, Ihe Trustees musl nol approve Ihe financial statements unless they are $8tisfied that they gNe a true and fair view of Ihe $tat¢ of affairs ol the Group and the Charity and of their incoming re$ources and ap￿icatIOn of resource$. induding Iheif income and expenditUTe, for Ihal perKrfJ. In wepa¢ing those fThn¢ial slalements, Ihe Trustees are mquired to.. select svilable accouniing wlioes and then 8ppky Ihem constslwtty.. observe the Meth￿￿$ and prinoes olthe Chanties SORP IFRS 102}". make judgernenls and a¢counling estimate5 that are reasonable and P￿￿ent. state whether applic8ble UK Accountin9 Standards (FRS 102} have been fdIcv￿d. subject to any material departures disclosed and e￿￿tsned in the firw)¢ial stalem8nls' prepe the financial stalemenis on th¢ 90in9 wKern basis unless it is inapproprie to presume that Ihe Group will continue in busirws. The Trustees are respC￿51b1e for keeping adequate ￿ountIng reCI￿d5 thal are Su￿len1 lo show and explain the Group and the Chariil$ transactions and dixtose wrth reasonable aeeuracy al any lime the tinancial posrfion ol the Group and the Charity and enabk them lo ensure that the financial slalemenls comply with the Companies kl 20(6. They are also reswn$1b￿ lor saleguardwig Ihe assets of the Grow) and th¢ Chaiity and hence for taking reasonable steps lor the pre￿Ilon and delects.cffl olfraL¢d and olher irregularilies. DI￿10$ure of Inf¢Ymation to audito Each ofthe petsons who are Truslees at the lime when thi5 Truslees. feport is aFvoved has confirmed Ihat". $0 lar as that Trustee is aware. there is no relevant aud￿ information of whKh the charitable group'3 audit91$ ar¢ unaware, and that Trustee has taken al Ihe steps th* ought to have bw) taken as a Trustee in order lo be aware of any rdevant audit informatkin aThJ to estst4.sh that charitable grwp's auditors a￿ awa￿ of ihat. informalion. Audltovs The auditors, K￿$t()n Reeves LLP. have indKated their ¥&illingness to continye in of1￿. The designated Trustees will propose a rnotion ieapwnling Ihe ￿￿rtly$ at a meeiry ofthe Trvslee& Approved by order ol the membws of the board of Tfvslees and s￿ned on their behall by.. Ms L Prlt¢h Chair pa￿ 14

The Brlllsh Allergy Foundat5on (A company limlted by guarantee) Ind•p•ndent auditots. r•port to the Memb•Tr of Th8 British Allergy F¢)vndatloTh Oplnlon We have audrted Ihe financial sL2tenRnts of The Bnts"sh Allergy Foundattm lthè'pafenl ¢han￿le compary'l and ils subsidiaries (the 'group'i for the year ended 31 Mar¢h 2023.vkni¢h conwri5e the Consolidaled slalemenl of financial xlivilies, the Consolmdaled balance sheet, the Charity balance sheet. the Con$olidaled stalemenl of cash Ilws and the rethd r70te$. including a summary of signifKant a¢winling p(1￿leS. The Iinancial rewrting framewo￿ that has been applied in th￿r preparakn'on is apPI￿￿e l¥ and United lfj'ng&)m Accounling Standards. including Financ￿1 Rwting Standard 102 'The Financial Repjrting Standard applicable in the UK and Republic of Irelan￿ (United KingJNn GeneraltyAccepled Accounling Pfxttt).. In our opinion Ihe finanual slalemenls.. gwe a true and fair view of the Slate of Ihe Group's of the parent charitable companls affairs as al 31 March 2023 and of the GfOUP'S iEKoming reswrces and appI￿￿10n of resources, induding rts income and expen<lilufe for the yearlhen ended., have been property piepared in actAyd¢e "wh Unite(l Kiffjdom Generally Accepled Accounting Practice.. and have been prepared in xcordance the requirements of the Companie5 Acl 2006. Charities Ad 2011. the Charities and Twslee Investment IS¢¢tkrKS) Act 2CK)5 and regulations 6 and 8 of the Charities Accounts ISGollandl Regthtions 20￿. Ba$1$ for oplnlon We conducted our audit in ac¢ordan¢e with Intemational Standaids on A￿￿￿1￿j (UK) {ISAs (UK)) and apphcable law. Our ￿SpoNSIbl1rtI¢S under Ihose standards are furlher (lescribed in the Audflors, responsibilities for the audFt of the financial statements section of our report. We are independent of the Group in aCc￿￿anCe wilh lh¢ ethical ièquiremenis that are relevant lo our audrt of the financ￿7 ststemenls in the UnAed Kingdom, including Ihe Finan¢ial Reporting Councifs Etht￿l Slandard. and we have lulfiNed our other ethical responsibilities in accorda￿ with these Tequirements. We belitrve that the 8udrt.eviden¢e we have obtained is suffirjenl and appropriate lo proMde a ba$is lor our cynion. Conclusions r•latlng lo going con¢m In auditing the financial stemenls. we have ¢(￿d￿ded th the Trustees. use ol the going concern basi$ of Countin9 in Ihe preparath.on ol the slalemenls is ap¢Yopriale. Based on Ihe worf( we have performed, we have not Jenlif*d any material uncertainlEs relating lo events OT condrtsons Ihal. indiwdualty OT eolledivety. may cast s￿nificant do￿)1 on the Group's or the parent charil8bl8 company's ability lo conlinue as a going ccfflcern for a period of al leasl (We￿ monlhs from when th8 financial 51alemenls are authorised lor issue. Our responsitslities and the responsi￿.1111es of Ihe Ttuslees with respect lo gr1￿ concern are descfibetl in the relevant 5e¢lions c4 this P4e 15

The Brltlsh All¢r9y Foundatton IA ¢ompany 1Smited by guarantee) Indep•ndont audltors. report to the Membets ol The Brllish All•rgy Foundatoon l¢ontlnu8dl Other infomiation The other informalion conwrises the infom)alhin induded in Ihe AnnLtal rewi other lttan thg financial statemenls and our Audit¢ys' report Ihereon. The Trustees arg responsib￿ lor the other hnfrymalion contain￿1 within 11 Annual report. Our opinlon on the finanaal" slalenEnls d￿S ncl wver the clher infomia1￿Th and. except lo the extent othemise explicilty stated in our report. we do nol express any forn ol assucance conclusion thereon. Our responsibilily 13 lo read the olher Infom￿lI)n and. in dcing so. consder thelher the olher infomtslion is malerialty incon$istenl wrth financial slatemenls t¥ rAJr krK)wle(Ige c￿lained in the course of thg audit. or olherwise appears to be maierially mi￿lat￿. If Klentify such material inconsi51encies or apparenl material misslatemenls, ￿ are reqvir¢d to determine whdher this gives rise to a material mi5Stalement in th& financial slalemenls Ihemselves. If, based on the wort we have performed. ¢ondude that there is a material misslalernenl of this other w)formatw)n. are required to rewl that fa¢t. We have ndhing to ieport in Ihis regard. Opinion on other matt•ts pr•scribed lry the Companl•s Act 200S In our opinion. b8sed on Ihe woth undert8ken in c￿rSe of the 8￿jit. the inlormation gI￿n in the TrUs￿S. re￿1 for fman¢ial yEar for whKh Ihe finarKiaS staleffnts are pr8pared is consistent wlh the fin￿¢1￿ sta18ments. Ihe Tiu$l¢es' repcyt has been prepared in acCOrd￿ce wrth 4)pk8blè legal requireme￿$. Matt•rs ¢)n which we ay• r¢qulr•d to report by excèplion In the light of our knowledge and underslanding of the charitable ccryany antl tts environment thtaineo in Ihe ourso olthe audit, we hwe not #Ientif￿1 wAlerial mi5$ts1ement$ in the Trustees. report. We have nolhing lo report in respect of Ihe folth¥ing matters in rela1￿ lo whKh Companies Acl 2[￿ the Chaidies Accounts Iscoitsndl Re9ulal)ns 20C6185 amended) require us lo report to you il, in our cyinion.. the parent charitaUe rompany has not kept adequate and w1￿1ent accounting iecords, Or r¥luins adequate lor our audit have not been reGer¥e(I from branches not visrted by us., 01 the went Chafilable cowrry finan¢iaJ slatemenis are nol in agieèmenl with the accounting records and returns.. or certain disck)sures of Tru51ees'.remuneTal)n by law are nol made.. ¢X we have not received all the infom7atK￿ and explanaiions we require for our atsdrt. or the Trustees were noi trnt1t￿d to prepare the finan¢ial ststemtrnls in Kcordance wth Ihe Small companies regime take avantag¢ of the small companE5' exernplion$ in prwring Ihe Trustees. ￿POrt and from Ihe requirement lo a Strale9i¢ feF¥Xt. Responsibilities of InJst••s As explain￿ more lully in Twstees. r$sp)nsitsI￿le$ stalemenl, Ihe Tr￿￿ee$ Iwlw are also the di￿¢101S of the charilable company for the purpos85 of company lawl are responstsle for the preparaiK)n of the financial slatemenls and for being satIsf￿d that gNe a true and lair vw. and lor such internal Control as the Trustees deterrninè is ne￿ssary ¢0 en)lè the p￿parall0n oi finawal slaternents that are free from material . mis51atement, whelher due lo fraud or error. In preparing Ihe financial sialen7enls. the Trustees are responsib￿ lor a55e5sing the Group's and the parent charitable companls ats'lty to conlinue as a goin9 concem. discktrsin9, as appl￿bIe,.matler5 related to going ¢on¢em and using the g￿ng C￿cern basi5 of accounting unless the Trustees wlher inlend lo liqu￿ale the Group or Ihe parent charilable ¢oftwany crf to cease operalions. or have no realislic ablemalive bul lo do so. Page16

Th¢ Brltlsh Allergy Foundation IA company 15mited by guarantee) Ind•p•nd•nt auditors. report to th• ol The BYili$b Allergy Foundation l¢onllnu•dl AuditOTS' rnspon$ibilItl￿ for th• audit of the financlal stat•ments We have been appoinled as auditor urnler section 44{1llcl of the Charits and Trustee Invest￿nI IScotland} Act 2005 and undef the Companies Act 20￿ and report in ac￿rIan￿ with Ihe Act and rekvanl regulations made or havin9 trffe¢l the￿￿nder. Our obiectNes are to ¢)blain reasonable assurance whether the financial statements as a whole are free from material missialernent. whether due lo fra￿1 or ermr. and lo issue an Audilcfs. Teport Ihal indude5 OUI opinion. Reasonable assurance is a hwjh I￿1 of assurance, but is a guardnlee that an audil conducted in accordance with ISAS (UK) witl ahvays delect a material mtsstatement when it exists. Misstalemenls can aii5e from fra￿j or error and are conwdwe(J malerial sf. indiwdualty OT W) Ihe aggregate. they Could reasonabty be expected lo influence the econonNc decisions of users laken on tho basks ol the$e finan¢ial stslemenls. Irregularities. Sncludry Iraud. a￿ mstances ol nonwc4Jmplice wrth Im aThJ regulal)ns. We design procedures in Ine wilh our responsibilities, r¥Jtltiied above, to delect material misstalements in respecl of irregularities, incknding fraud. The exlent lo vthtth our prccedures are capable of detect¥bg irregularities, inclLKling fraud is detailed belovr. capa￿lity ollhg audit in d9{KIN￿ iryth8niie4 I￿￿U￿n9 Ir8ud Based on our LFnderslanding of the charity arwj Ihe sec¢or 8$ a 8rKI through discussion with the Trustees and other management 13$ requir￿ by auditing standards}, we hlentified that the princApal risks ol non- compliance with laws regulalion$ rdated to heahh artd safely and employrnent kn. We ¢onsidered the extent lo whKh non<ornpliarfce mMJhl have a material effect on the linanaal statements. We also considered thD$e laws and fegulations that have a (Jirect impacl on the prepaTal•Jn ol the finarKial statements such as the Charrties SORP (FRS 102) Second Edition {released Odober 2019). the Companies Acl 2006, laxalron and p.en$ion legislat)n. We ¢ommuni¢ated KIentif￿d Iwws wvlations throughoul our learn and remained alert lo any indications of non-compliance throughout the audit. We evaluated management's irtcenlwes and opportunities for fraudulenl manipulalw of the financ4al staterr￿lS {inclLJing the iisk of override of contrdsl, and detemiined that the principal risks were relat￿ to inc¢yrect re￿3n￿tiOn of legxy income, posting inappropriate joumal entres aThY magement txas in accounting estimates and judgemenlal areas of the lina￿la1 statemenls. Audit prccedures performed by the engagement leam in¢fwJed'. . DiscussK)ns y￿tt managemenl arKI assessment of krKwn or suspec￿1 irtsiances of non-C(¥npliance with laws anLI regulat￿)rts {inchJding health and safety) and fraud.. and Assessment of identified fraud iisk factors,. and Review of expendituce to ￿nfi￿ no wden¢e ol personal benelrt". and Identif￿h9 and assessing Ihe de4n effediveness of controls that Mar￿je[￿l ha$ in place to prevent and dele¢l fvaud," and Challenging as5uffylions and judgernenls made by management in its sKJnrficant accc4Jnling eslimales,. and Pertorming anaI￿lea1 procedures Io klentrfy any unusual or unexpeded lelat￿anShIP$. in¢luding relaled party Iransactions. thaimay indicate risks ol material missiatemenl due lo fraud.. and Conlirrnalion ol related partV6 with management, and review ol Iransadions throughout the peiiod lo idenlify any previousty undisclosed Iransactions with related parties outside Ihe nom)al course ol business,. and Reading minLrt¢$ of me¢ling$ of those charged with goverrwice,. and Review ol sigllificanl and unusual Iransactions and evaluation ol the underfwng financial rationale supporting the transact￿nS., and Idenlilymg and teslin9 joumal entries. in p*li¢ul¥ any manu81 enlries made at the year end lor financial statement preparalion. 17

The 8rltSsh Allergy Foundation IA company lifflit¢d by guarant•e) Independent auditors. report to th• Membvs of Th• Brilish All•rgy Foundation l¢ontlnued) Because. ol the inhwenl l¥nitslion$ of an a￿￿rt, the￿ is a risk Ihal TMI not deteci all irreg4Jlarrties. ￿ClUdIng those leading to a malerial misslalemenl in the finanual statements or n￿•cOrr￿￿4rtc¢ with rtgulalion. This risk increases the more that compliance wth a regulath)n L removed from Ihe events and Iransadions reflected Hi the financia slatemenls. as ¥￿ be less likety to become aware of inslanees of nc￿-coMplW1¢e. The risk is also grealef regafding Kregularities (Kcwring due to fraud rather than ¢rrw. as fIal￿ inv(Aves intenlional concealment, foryery. collusion. omission ￿ misrepresentstion. As part of an audit in accordance wilh ISA$ {UKI. we eXe￿ise prolessK)nal 1￿jement.and maintain professional sceplvsm throu￿¢ Ihe audit. We also: Identify and assess the Tisks ol material misstatement of the [￿anJal $t8tements, whelher due lo fiaud or efror. design and perform audit prLvdures responsNe to those risks, and olAain audit ewden¢e Ihal is sufficient and appropriate to Prov￿￿￿ a basis for our wnion. The iisk of not dete¢tbrs a maleiial misslatemenl resullity from fraud is hwjher than for resulting fiom erior. as fraud may invofve collusion. forgery, intentional ￿nIs510n$. miyepresenlations, Of the overiide of ￿tornal conlrol. Obtain an understanding of internal Contr￿ relevant lo the a￿111 in ￿der to des3n audil pr￿ed￿r¢S that are appropriate in the urcurnstances. but nol for the ol expre55ng an opinw of Ihe effeciiveness olthe charitable ¢(npan¥$ inlernal ¢￿r01. Evaluale the approprBteness of ac¢ounting pofi¢is.used and reasonabkness of accounting eslimales and reLgled di5dosures made by Ihe Truslee5. Conclude on the appropriateness of Ihe Trustees. use of the gomg concwn basis Of.ac￿unlIn9 and. based on thè audit eVKIen￿ r)btsined. thelher a material uncertainty exists related to event$ or ¢ondittons Ihal may cast signfficanl dwbt on the chanlable companrfs abilily to continue as a ping concem. 11 we condude that a rnaleJial uncertainty e￿51$. we a￿ required to draw altention in our Auditors. report to the related disclosures in the financh?I staterr￿n1$ OT, il suth disdosures are inadequate. lo modfy our opinion. Our conclusions afe based on the audit evhlence obtained up lo thè date of our Audrtors. report. Hwever, future ￿ntS or condrth)n$ may cause the charlale c4)mpany lo cease to ¢onlinue a$ a goin9 concem. Evaluate the overall presentation. struclure and ￿lten1 of the finan￿1 statements. induding the disclosures, and whelher the finanaal S&￿ements represent Ihe under1ww Iransa¢ll￿5 and events in a manner thal achieves fair presentalKJn. Obiain Suff￿lent appropriale audrt evthnce regarding the fInanCk￿ informa!K*n of the enlbties or business actiwties ￿thIn the Group lo express an opinK)n on the consolidated financial ststemenls. We are responsible for the 5upeMsion and perfomian¢e of Ihe Group audrt. We remain solely responsible for our au(lit op¥iion. We communicate vAth Ihose charged wlh govemwce regarding. amL¥vJ clher maiters. Ihe plamed scope end liming ol the audil aThl signrficanl audrt findings. including any svJiMficant defwici$$ in inlemal conlrol that we Jentify durin9 Ouf audil. Page18

The Britlsh Allergy Foundaiion IA ￿rnPany limiled by guaran¢e•l Independent auditors. Teport to th• mom￿19 ol The 8rltlsh Allergy Foundation Icontlnued) Use of our r•port This report is made solely to the charitable companys rnern￿. as a bLJy, in accordance %wth Chapter 3 of Part 16 of the Companie5 Act 2006, and lo Ihe charitsble CrynpaTr￿s Iru$lees. as a b¢)ty. Part 4 01 Ihe Charities {Accounts and Reports) Regulat)ns 2C)8 and regulation 10 of the Clwitigs Accounts (Scollandl Regylations 2006. Our audil WOTk ha5 been undertaken so thal we mwhl state to the charitle ¢¢Anpanl$ mambers Ihose mallers we are required to state to them in ￿ AU￿rt￿s, report and for no other purpose. To the fullest extent permilled by law. we do not accept or assume responsibilily. io anyone other than Ihe Charitable company and its members. a$ a b¢¥ly. •rdit w￿, for this report. or fof the opinion$ we have lorm8d. Il.,k Les LLP Samantha ROU￿ FCCA DChA IS•nloi slatutory audltorl f(w and on behalf of Kreston Reev•s LLP Chartered Accounlants Slalulory Auditor Canlefbury Dale.. 30 November 2023 Kreston Reeves LLP are elvjible lo act as audrtor5 n tem￿ of $￿iDn 1212 of the Cryanies Act 2006. Page 19

Th& Britlsh Allergy Foundation IA company limlted by guatant••l Consolldated Statem•nl of financlal xtivllies (In¢orporating I￿Ome and oxpendlture ac¢ounti For th¢ y￿r ènd•d 31 March 2023 Unrèstricted ReStrI￿ed funds lunds 2023 2023 Total lunds 2023 Total hjnds 2022 Incom• from: Donalions and legxies Charilable activities Other Irading a¢tMties Inveslmenls 36.265 22.410 1.338224 5.691 122.258 150.523 22.410 1.338,224 S.691 77.021 2,237 1,569,234 2,043 Total incom• 1,402.S90 122.258 1.524.848 1.650.535 ExpenditUT¢ on: Raising funds Charitable activrttes 255.682 1.386,245 31.290 286,972 1.388,245 458,317 1,245,885 Tolal frxpendllure 1.641.927 31290 1.673217 1,704.202 Net movem•nt In funds 1239,337) 90,968 1148.3691 153,667) Reconclllation ol fuftds: Total funds broughl frI￿ard Nel movemenl in funds 1,100.610 1239.337) 15.089 90.968 1.115.699 1148,3691, 1.169.366 {53.6671 Total lund$ ¢afrl¢d forward 861.273 106.057 967,330 1.115.699 The Consolidated statement ol financk8l•clr4rt￿ wKludes all gains and 105ses recognised in the year. ' The notes ¢M pages 14 10 36 lomi part ol these financial statements." Page 20

The British Allergy Foundation IA ¢¢mpany limited ty guarantee) Regislered nuThber.' 04509293 Consolldated balan¢e sheet As at 31 Mar¢h 2023 2023 2022 Flx•d assets Intangible assets Tangible assels Inveslm8nt$ 13 14 92.521 17.227 14 130,517 27,431 14 15 109,762 157,962 Current a$$•ts Sto¢ks Debtors 16 17 961 294,920 462.249 520.WJ6 761 388,254 Investments. 18 Cash al bank and in haThJ 846.276 1.279.026 1.695,291 Credilors.. amounts falling due wrthin 19 1421.4581 {737.$541 Not current awts 857.568 957,737 Total n¢1 assets 967.330 1,115,699 Charity lunds Rostricled funds Unreslricted funds 106.057 861.273 15,089 1.1(Kl,610 20 Tolal lund$ 967.330 1,115,699 The Trustees acknowfedge their ¥esponsily"Ittie$ fL¥ comth'rvJ with th8 requwgmenls ol the Acl wlh re5ped lo a¢¢ounling r¢¢ords and prewalion of financial statements. The financial stalemenls ha￿ been prepared ir) a(tord#nce wth the provisions applicable lo entities subjecl lo the small companies regime. The financial slalernenls were approved and aulhorised lor r&sue by Ihe Truslees and signed on their behalf by.. MSLP Chair hard Dale.. f S4'V The nol•s on pages 24 to 50 lomi part ol these financial stalements. Page 21

Th• Brlllsh Alkryy Foundatloft (A company limlted by guarant6e) Reglstered numI￿r. 04509293 Charfty balance sheet As at 31 March 2023 2023 2022 Note Flxfjd •$$et$ Inlengibk 8ssets Tangible assets Investments 13 14 15 92,521 17,037 16 128.226 26.719 16 109.574 154.961 Current assets Slocks Debtors Investments Cash al barf< and in hand 16 17 18 961 211.061 462249 260287 781 381.879 460,000 283,097 1.125.737 Credilc¥s'. amounts14lling due within one year 19 193.6231 1186,1801 Net current assets 840.925 939,557 Total net assets 960.499 1.094.518 Charity ftsnd$ Reslrided furK15 UnreStr￿led funds 20 20 106.057 844.442 15,089 1.079.429 Total lunds 950,499 1.094,518 The Charttls nel ryhmrnenl in.fuThJs lor Ihe year wa5 £1124.331112022- £{53.e67)>. The Tiustees aCknth￿e￿ge the¥ responsiblities lor compl￿"nY wth the requirements ol the Act with respect lo accounting records arKI preparat￿ of financial 51atemenls. The financial $talets￿Ats have been prepared in a¢￿[dance wth the Fffjw$ions aprArable lo ￿lIt￿$ subiecl lo the small companies regime. The financial $lalem¢nl$ were approved and ault*YF"sed for issue by Ihe Trustees and signed on theif tsehalf￿￿. Ms L Prltchard" Dale.. The noles on p&Jes 24 10 SO lo￿ part ol these fifta￿la1 slatements. Page 22

The British Allergy Foundatlon IA company limited by guarantee} Conso11dat￿ Si•iement of cash flows For tho year end•d 31 Ilarch 2023 2023 2022 Cash flows from opwating *ctlvltles Net cash (used inyprovidèd by ￿kn¥￿ie3 23 1327,0711 127,3631 Cash flows from Investlng actlvhlos Interest received Purchase of inlan9ible assets Purch8se of tangible fixed assas Purtha5e of inveslrnents Decreasellincrease) in short tem) deposit acrAJunls 5.691 15501 11,2011 2,025 (23,7591 (13.114) 141 393,098 (2,2491 Net cash provlded by Investlng actlvltles 1.691 358,246 . Change in c•$h and cash equlvaknts In the ye Cash and.cash gquivalents al Ihe be9innirrfJ of the ye 1326.380} 846.276 330,883 515,393 Cash and cash equlvalents at Ihe end ol the year 24 520,896 846,276 The noles on pages 24 to 50 form part of these fin￿Cial statements Page 23

The British Allefgy Foundatlon IA ￿MpanY Ilmited by guarantee> Notes to the flnancial statements For lh• year ended 31 March 2023 General Infomiatlon The Bvrt15h Allet9y Foundth"on is a Charitab￿ prNate ¢(wny ￿mIl￿1 by guaranieg. incorporated in En9land. Wales and S¢oUarbJ. The Iwbilty of each member in the e¥￿t of a windin9 UP bs limil•J lo £1. The registèrèd office is LorKlon Hov5e Busines$ Centre. Tharftes Ro&J. Craylord. Dartfofd. England. DA1 4SL. The principa ath.vity of the Cha1￿y KS lo increase awaieness of al￿rgY and causos of ￿aphwaX{S through seNi¢es, advo¢a¢y. ¢8rN)aigns for poliGy and kgiskili¢Jn changes. education on management and wevenlion ol allergy, supporting the allergK commLtnity. promoting research inlo causes of allergy and irnwroving quality othfe. advcKacy. vice. supwt and information servKes. A¢countlng pollcies 2.1 Basls ol preparatlon of flnan¢lal stal•ments The financial stalwi)ents have been prepated n a¢¢ordance wilh the Charities SORP IFRS 102) - Accounting and ReportirvJ by Charities." Slalemenl ol Recommended Practice appfficable to ¢harlI￿$ preparing their axounts in ￿allce wth Ihe Financial Reporting Standard applicable in the UK and R¥puNK DI Ireland IFRS 1021 (effeetive 1 January 2019}, the Financial Repohiig Standard applieable iri the UK and Republ￿ of Irelarml {FRS 102) comp￿leS Ad 2006. The Brrtsh Alkngy Foundation rnee15 the definrfion of a publK benefit entity under FRS 102. Assels and liabilities are initialy reCC•Jni￿ at histoiical cost w tr)saction value urAess otherwise sialed in the ielevant acC￿￿tIng policy. The Congc4Trdated statemenl of fmno81 adwt￿ (SOFA) and Consolidated balance sheet consolidate the financial slalements ol the Chaity * its subskliary undertaking. The results of Ihe subsidiary ale consolthted on a line by line basis. The Charity has tak•n a￿antage of the exemplion alltred under 408 of the Companies Act 2rxfi and has nol presented its th ststement ol financial ac11vil￿$ vl these financial sl8temenls. Page 24

The 8ritlsh Allergy Foundation {A company Itmlt¢d by guar4n1￿) Notes to the flnanclal staloments For the year ended 31 March Z023 Accountlng pollci•s Icontlnu•d) 2.2 Income All income is re¢ognised (￿ce the Chanty has enlillemenl lo the in¢om¥. after any performance conditions ha￿ been met. rt k8 probable that the inwne vill be receNed and the nounl of wKome receivable can be measured relthty. Incoming reswrces frm tharitable li&Jing actrlrties a￿ recognwl a$ folhyws.. The 50le of goojs. re¥erwJe 15 reccgnised when dMd g¢x•J$ are sokl. The iendering of servtces- revenue i8 re(ryniseil as follcms.. Applutions for Ihe seal of approval when the appbcalion has been sNJned and the Iwm$ agreed., Renewal of Ihe seal of approval the monlh of ¢onYnencemenl ol the new period" and Services. such as training. m the the seNice$ are supplied. Vc4unlary I[￿Me is received byway of gran1$. donions. legacies and gifts and is included in full in the Slalewnl of Financial Aclpirtie5 vthen r￿e1¥able. Grants. where entitthent is not conditi.onal on the delNery of a Spear￿ performan￿ by the chwty, aw ￿09Th1$ed when the ¢hanly becom￿ unconditionally enlilw lo the y[￿t. Incoming resowces fr(m grants. fiere ￿lated to perfrmwce and specfft deliverabks. are accounted for as Ihe charrty eams Ihe rMJhl to cons#JeialK)n by rt5 perfoThMnce. Inves1nw￿ income 15 induded when rerivable. Legxies are indude(I when Ihe Chènty has legal enlrfement. the amount can be measured re&abty and it is prcbable that the incoft will be feceived. Income tax recoverable in relation to investment incOff￿ is fecoynised at the time tho investment ir¢om¢ ts r•c8ivable. 13 Exp•ndllure Resources expended are included in the Statement ol FinarKl Aclwrties On an ￿rUal basis and have been ¢lassifRd under headings th* aygre9aie 811 ¢osts related lo the category inclusive 01 any VAT which cannot be recovered. Expendilure is recognised where the￿ is a legal or constructive d)ligalion to make paymènl to a third party. il is probable that selllemenl will be fequired and the amounl of the obligation ¢an be measured reliabty- Fundraising cosls are those incurred in seekir¥J voluntary contributions and the staging of lundraisiThJ events. Support costs Support cost$ are Ihose ¢osls inCw￿d dwectty in support of expenditure on the objects of the company. 2.4 Gov•inm•nl grants Income from governmenl granlg is included at Ihe poinl ol applicalion for the fvnds if Ihat funding is considered lo meet the criteria of rneasurabih"ly. ieliabilty ahd probatsilty. (Xherwise il is accounted Icw upon receipt Page 25

The Brllish Alleryy FoundatioTr {A ¢ompany Ilmbted by guaranle•) Nol¢$ to the flnancial stat•ments For the year ènded 31 Mar¢h 2023 Accountjng pollcigs l¢onllnu•d) 2.5 Foreign currtncies Mone18ry assets and liabilitses d￿K￿Mated in f￿agn currencie5 are translated inlo sterling at rat¢$ of exchange rulirvJ al the TepC￿￿"n9 dale. Transaclions ￿ I￿e19n currencs are translated into sterling at the Tale Tuh'ng on the dale d the Iransaclion. Exchange gains aNI losses are recognised in the Consc4idated stalement of financial activities. 18 Inlangible assets and amortisation Inlar#Jible assels c05ting £1.OCrtJ or mtre ao capitalssed and recc3nised when future e¢oMmic benefits are probable and Ihe cosl or vahje of Ihe assèt can be meaSu￿d reliabty. Intangitjle a5sels we inrtia4y recc4Jnised at cost. After recognitian, under the cost model, Int￿Ible assets are me8sur•l al cost less any xcumulatsd 8m¢ylisatK)n and any ￿￿n￿lated impairment losses. Amorti$alion is provpjed on intangble assets al rates cakukled to ￿lIe off the cost of each asset on a straight-line basis over ils expected uselul lrfe. hrnorti5alion 15 promded on the bases: . Website CRM Oevewnent cosls 10 % slraight line 10 % straight line 17 Tanglbl¥ fix¢d assets and deprecialion Tangible fixed assets ¢ostirvJ or mcrfe are capilahwj and rewjnised when luture e¢onom benefrts are probable and the cost or v￿ue ollhe asset can be mea5Ufed reliabty. Tangible ffixed assets are iiNliay re¢c9ntsed at ¢o$t. After re¢ognilKn. under the ¢ost model. tangible fixed assets are measured al ¢05t kess aCcumU￿1ed depreciation and any accumulated impaiimenl losses. All costs iwjrred to bring a langible fixed ass&t into its inlended workirKJ condition should be in¢1￿￿ed in the measufement of cosl. OeprecialKJn 1$ charged so as Io allocate the cost of tsngiNe fixed assets less their residual value over Ih?IK esb"rnaled useful I￿$. on a re(lucing balance basi5. Al new r￿ed assels purGhased in 2022123 and s[￿seqUent￿ are depfeciat8d on a slrawJht4ine basis. oewetyatK￿ is on the folhymng bagL8". Furniture and filtings Conyyuter & offKe equipment 25% reducing balance 25% redvcing balance 2.8 InvestmeDI$ Fixe(l asset investments are a form of financial instrumenl an¢J a￿ Init￿ty I￿09n$Sed al their transaction cosi aThY subseguentty measured at fatr value at the Balarte sheet dale, unless Ihe value eannol be measured reliabty in which case rt is measufed at cost less wnpairmenl.Jnveslmenl gains and losses, whether ￿¥ll$e￿ or uniealised. are combined and presenled as 'Gainsl{Los3es} orn inv8slments' ui Consolklaled slatem&nl ol financial a¢lNities. Investments in subskliaries are valued at C051 less prOVts¥￿ for impain)enl. Page 26

The British Allèrgy Foundatlon IA company limlt¢d by guaranle• Notes to tht finan¢lal staiements For the year ended 31 March 2023 A¢counllng polkiw l¢ontlnu•dl 19 Stocks Slo¢ks are valued at the F(xr of ￿st and net realisable value, being the eslimaled sellin9 price less costs to Co￿vI￿te and sell. Cost is based on Ihe cost of purchase on a first in, first oul basis. Work in progres$ and finished gcKl$ in¢We kbour and lributable ovetheads. Al each balance SW dale. stocks a￿ assessed for impaimnl. 11 slcd( is impaired. the carrying amount is reduced to ils selling pri¢e ￿$15 lo compkio and sell. ThB impalm￿l foss is iecognised immedtalety in profrf or loss. 2.10 Oebtors Trade and other thblots are reeognwd at the seltlement w￿unI after any Irade discount offered. Prepayments a￿ valued 8t amount prepaid net ofany trade discounts due. 2.11 C•$h at bank and In hand Cash al bank and in hand ￿ludeS cash and short4erm h￿hty liq￿d inveslmnl$ wilh a short maturity ol Ihroe montPts or18s$ frtyn the date of a¢qUisit￿n ￿ opening of the deposrt Crf 3unilar a¢count. 2.12 L.labiliti•s and provisions Liabilities are reco3nised when Ihete is an C￿l￿10n at the Balance sheet date as a Tesull of a past event. it is probable lh a Iransler ol econ(¥nic benerrt will be required in seltlement. orKI Ihe amount of the selllemenl Can be e51Thaled reliabty. Liabilib"es are recognised 81 the am¢)unl that the Chaiity ankn'cipaies il pay Io Sett￿ the debt or the amount il has recwved as advanced payinenl$ for the gc<•Js or $eThices rt must provKIe. ProVis￿n$ are measured at Ihe best estimate ol the amlwnts required to settle Ihe obligath￿. Where the effecl ol the l¥ne value of money is malerial, the provisKJn is based on the present value ol those amounts, discounted at the pré4ax discount rale thal reflects Ihe risks 5t)e¢ifi¢ to the lia)ilrty. The unwnding ol the dis¢rM)l 1$ recogntsed in the Consoh"dated statement ol fffiancr81 octivilies as a finance c051. . 2.13 Frnanri41 Inslrum•nts The Group onty has fnawal assets and financtal IkqbililEs of a kind thal qualfy as bas￿ financial instruments. B8si¢ finan¢k41 inslrvmènls are inilkalty recc¥Jnised al Iransaction value and subseouenlty ' measured at their Settlement value wrth Ihe exception of bank bans whith are subsequently measured al amortt5ed cost using the effeclive interest method. 2.14 Operatlng leases Rentals pwd under s)perating leases are charged to the Consol*Jaied Slat8rnenl ol Financial AclNilies on a straMJh14ine basis over the lease term. 2.15 Penslons The GTOUP operates a defined conliibulion Pens￿)n scheme the pens￿￿ charge reP￿sentS the amounts payable by the Group to the in Tespecl ol the year. Page 27

Thg Brlllsh Allergy Foundation IA company Ilmlted by guarante•l Notes to the finanelal $tat•m•nts F¢r lh• year ended 31 March 2023 Accounting poli¢i•s l¢ontinu•d) 116 Fund •¢¢ounling General fund$ are unreslrided funds vthich ￿e available IOT use at the discret￿)rt of th Trustees in lurtherance ol the general c￿lectr￿S of the Group an<1 YthKlJ have nol been designated for other purpose$. Oesigned funds ccmwise unl￿triCted funds that have been sel aside by the Tru$tee$ f¢y path'cular purposes. The aim and use of each dwnaled fund Trs sel oul in the Mtes lo the financial slat¢monls. Reslricled funds are funds which are lo be used in ￿rdar￿e wth specific restr1d￿1n5 imposed by donors or wh￿h have been raised by the Group for particular purposes. The costs 01 I8ising 8nd administering such Ivnds are charged against the Specif￿ fund. The aim and use of exh Teslricled fund is set oul ii the rths t¢ the financial stslemenls. Investment in¢c*ne. gains 8nd losse$ are ollcrtaled to th¢ apprcyriate fund. Income Irom donations and legacles Unrestricted Restricted funds nd$ 2023 2023 Total lunds 2023 t1(￿atIonS Grants 36,265 36.265 122.258 122.258 36.265 122.258 158,523 . Unrestr￿ed fund$ 2022 Restricted funds 2022 Total funds 2022 tlorkali￿s Legacies Grants 34.971 16.375 11,000 34,977 16,375 25,669 14.669 62,352 14.669 77,021 P￿e 28

The British Allorgy Foundatlon {A company Ilmlted by guaranteel Notes t¢ the flnanclal stalernent$ For the year ended 31 March 2023 Income Irom Charilable *¢tiviti•s Unrèstricted fund$ 2023 Total funds 2023 Total fvnds 2022 Sale of translation cards Affiliate markeliTrJ Fee3 received 22.005 1.982 405 250 . 22.410 22,410 2,237 Income from ￿her tradlng •cti¥ities Incom• from fundrnising •v¢nts" Unrestri¢ted fund5 2023 Total funds 2023 Tol81 funds 2022 Fundr•sin9 even15 20.918 20.918 20.298 Incom• fmm trodlng sub5idlary Unr•stricted funds 2023 Total funds 2023 Total lunds 2022 Seal of approv Renewals Alleigy Friendty Produd$ Corporate partners Akrts 357.81 S 689.894 60,700 205.￿0 3.120 777 357,81S 689.894 60,700 205,000 3.120 777 479.602 642.675 81,650 355,819 3.725 5,465 AlergyAwareness Scheme 1.317.306 1,317,306 1,548,936 Page 29

The 8rftl$h Allergy Foundation IA company limited by guarantee) Note$ to the fin4n¢Sal sialem¢ffits For the year ended 31 klarch 2023 Investment Income Unrestrlcted lunds 2023 Tolal .funds 2023 Tolal funds 2022 Inl&resl received 5.891 5.691 2.043 Expendltur• on ral$lng fvnds Co$ts of raising voluniary incom• UnrestTi¢tod I￿ndS 2023 Total lunds 2023 Cire¢l costs Professional fe 2.178 2.653 2.178 2.6S3 4,831 4.831 UnreslrKled fLtnds 2022 ReslrKted funds 2022 .Tol funds 2022 recl costs Profession81 fee$ 8.845 5.425 60.319 69,164 5.425 14,270 0.319 74.569 Fundraising Ir•ding eXpe￿$￿S Unrestri¢ted Rostrlcted funds lund$ 2023 2023 Total funds 2023 Fundraising expenses 9,132 31.290 40,422 Page 30

The British Allorgy Foundat#)n IA company limlied by guarantee) Notes to the financlal $t4t?mtnts For the y¢ar enqled 31 March 2023 Exponditure on ialslng funds l¢ontlnu•d) Fundraislng trading exptrn5es Icontinuedl Unreslri¢led funds 2022 Total fund$ 2022 Fundra$in9 expenses 30.396 30,396 Expendituie on tiading $ubsidiary Unrestrlcled fund$ 2023 Total funds 2023 Total funds 2022 Cost of sales 241.719 241.719 353,332 Anatysis ol exp•ndltur• on ¢harltsble aciivities Summary by lund type Ilnfestiicted funds 2023 Total 2023 Charitable a¢lNI 1,386.245 1.386,245 Unrestl￿ted funds 2022 Restncled fvnds 2022 Total 2022 Charitable a¢tiwt 1.244.055 1.830 1,245.885 Page 31

Th¢ Brltlsh Allergy Foundatlon IA compaw limbted by guarnntee) Notsts to Ihe linan¢lal Btatenwnts For the year end•d 31 March 2023 Analysi$ ol éxpenditsre by actlvitl¢s Actlvities undertaktrn direct 2023 . Svpport costs 2023 Total lunds 2023 ChariLth actNit 1.024.622 361.623 1.388.246 A￿l￿tIeS urKlwtsken direct 2022 SupFQrt Total funds 2022 2022 Charrtable activ* 878.440 367,445 1.245.885 Axalysis ol direct costs Tolal lunds 2023 Total funds 2022 staff ¢o$ts Communications Other direct ¢￿ts 877,828 127.360 19.434 7S7.225 101,521 19.694 1.024.822 878,440 Page 32

The Brllish All•rgy Foundation IA company limfted by guarantee) Notes to the flnanclal statemenls For the year ended 31 March 2023 Anilysis of expen(liture by actlvities Icontinued) Analy$l$ ot support costs Total f￿ndS 2023 Total fvnd$ 2022 Prernises Communulions Legal & proles￿On81 General Olf￿ expenses Depfecialic F#iancial charges Goveinance costs Trustee meetings 117.758 5.292 32.889 111.753 27.450 31.$06 34.976 140.063 3,261 50,079 119.679 27.779 13.122 12.250 1212 361.623 367.445 10. Avditors. remuneration The auditors, remunerat*￿ amounts to an auditor fee of £10,350 r2022 - È8,500). and remuneratiorb in relation to the preparalK)n ol Ihe financial statements and Co￿￿"0n lax returns of £4,125 12022 £3,750). Page 33

The Brltish Allergy Foundatlon {A company limited by guarantee) Notes to the financlal statements For the y•or end￿ 31 Ma￿h 2023 11. Stsff costs Group 2023 Group 2022 Chartty 2023 Chaiily 2022 Wage¥ and salartes sock￿ secunty cosis Contribution to defined ¢ontrthition ynsion schemes 783.375 74.217 670,528 62.979 781375 74,217 670.528 62.979 20.236 23,718 20,236 23.718 877.828 757.225 877.828 757,225 Tw ex￿ratia payments were made with regards to sewement agreeme￿$ made by Ihe ¢harity {2022.. Nonel. The Ch￿lY feft il had a moral ob1w1￿ lo make these paymenls in recognilffi of th¢ indNiduals' contribution lo the charity. These ex4Jratia payinents t01al￿d £8.940. one of wh￿h was accrued al the year end wilh a bakn¢e of £3.50012022:"£Ndl. Tho average number of Pgfsons er￿ by the Chaiity d￿n9 Ihe year was as fo1ry4VS'. Group 2023 No. (oup 2022 No. Charity 2023 No. Chafity 2022 No. He8d¢¢)uftl 23 26 23 The average heade￿nI expressed as full-lime equ[a1￿1S was.. Group 2023 No. Group 2022 No. Chadty 2023 No. Charity 2022 No. Chairfable actiyities Generaling funds 19 12 19 12 22 19 22 19 The number of empbyees whose emp￿￿ benefrts {ex¢tsJding enwbyer pensiw wstsl exceeded £60,000 was". Group 2023 No. Group 2022 No. In the band £60,001- £70,000 In th8 band £70,001- £80.000 The key management personnel of the group comprise the Board of Trustees. Ihe Chief Executive and Operalions 01￿clor (prior year onty the Twstees and Chiel Executive). The total ernployee benefits of Ihe key managemenl personnd ol the group were £149.32812022- £84.0691. Page 34

The Brilish Allergy Foundatio IA company Ilmited by guarantee) Not•s to th• linan¢ial stalem•nts For the y¢•r ond•d 31 March 2023 12. Trust•￿. rnmun•ratlon and •xp8nsos Durirfj the year, no TrU￿ee$ recefftd any remuneratw or other beneffts {2022 - £NIL}. Duriro the year. ended 31 March 2023. expenses lotsling £2,823 wete reirtiursed or" paKI dir8cUy lo 5 Trustee$12022- 2 Trustees received a total cl £1.1781. These related to lrnvel and hotel costs lo altend Board meetings. 13. Intangible assets Group CRM Development Costs Website Total Co$1 At 1 April 2022 Additions 107.102 550 150.562 257.664 $50 Disposals 132.7211 15,9181 138,6391 At 31 March 2023 74.931 144,644 219,$75 Amortisatlon At 1 April 2022 Charge for the year 64,173 5,983 62.974 15.056 127.147 21.039 Al 31 March 2023 51310 75.844 127,054 Net book valu At 31 Mar¢h 2023 23.721 68.800 92,521 At 31 March 2022 42.929 87.588 130,517 Page 35

The 8rltlsh Allergy Foundatlon IA company limited by guarantee) Nolas to the fmanclal statefflenls For the year end￿ 31 March 2023 13. Int•ngibl• as$•ts l¢onlinu¢d) Ch*ity CRM D•v•lopm•nt Costs Websbte Total Cosl At 1 ApiA 2022 Addrtion$ Disp¥)sals 102,546 150.$62 253,108 sso (34.0831 128.1651 KIS,9181 144,644 Al 31 March 2023 74.931 219,57S Amortlsatlon At 1 Apfil 2022 Charge lor the year 61.908 S.$6S 62,974 15.056 124,882 20.621 At 31 March 2023 Sl,210 75.844 127,054 Nel book ¥•lue At 31 March 2023 23,721 68,800 92,521 At 31 March 2022 40,638 87.588 128,226 Page 36

The Britl$h Alltrgy Foundation IA company limlted by guarantee> Notes to the flnanclal statements For tho year end￿ 31 Ma￿h 2023 . 14. Tangibl* fixed assots Group Comput¢r & ofllco equipm•nt Fumlturè & fittin9$ Total Cost or valuatlon Al 1 April 2022 Addrtions Disposals 61.911 86.777 1.201 (34,4071 148,688 1,201 {81,8631 147,456) At 31 March 2023 14A55 53.571 68.026 Depmclatlon Al 1 April 2022 Chaige lor the year On disposals 48.992 3.160 {45.318) 72.265 3.829 132.129) 121.257 6.989 {77,4471 Al 31 March 2023 6.834 43,965 50.799 Nel book valu• Al 31 March 2023 7.621 9.606 17,227 At 31 March 20Y2 12.919 14.512 27,431 Page 37

Th¢ Brltlsh Allergy Foundatlon IA company lin*ted by guarantee) Note$ to th• finan¢lal ststThnts For tho year ended 31 Ma￿h 2023 14. Tangible fixed assets Icontinuedl Ch•rity Computor & office equipmgnl Furnlture & fft¢ings Total Cost or ¥aluatlon At 1 April 2022 Addrtions 'sposals 61,911 71,720 1,201 122,0131 133,631 1.201 169.469) 147.4561 At 31 March 2023 14.465 65,363 Depreciation At 1 April 2022 Charge for the year On disposals 48,992 3.160 145.318) 57,920 1,670 (20.098 106.912 6.830 165.4181 At 31 March 2023 6￿34 41,492 48.326 N•t book value Al 31 March 2023 7.621 9,416 17.037 Al 31 March 2022 12,919 13,800 26.719 Page 38

The 8rblish Allergy Foundatlon IA company Ilmited by guar4ntsg1 Notes to the Ilnan¢lal statement5 Foy the y•ar ended 31 March 2023 IS. Flx8d ¥￿t Investments Inveslments In subsldlary. panles . Group Cost or v*lyatl¢)n At l April 2022 14 At 31 March 2023 14 Inv￿lm8nts subsidiary ¢ompanies Char5ty Cost or valuation At 1 April 2022 16 At 31 March 2023 16 Page 39

The Brit15h Allergy Foundatlon IA company limited ty guoiantet) Notès to the flnan¢lal stat•m•nty For the year ended 31 March 2023 15. r￿fjd asset Investments (¢ontlnued) Prin¢lpal $ubsldlarles The foll¢Ning were subSTdiwy L￿dertaking9 of the Charity. N8mes Company Reglst¢red office or Class of Holding In¢luded Sn numb•i prlncipal place of buslness shares Con￿li￿all0n Allergy Researth Ltd 03550847 Plwmell House Lefa . . ord￿ary 1CQ% Yes Business Park. Edgiryton Way. Sidcup. Kent. DA14 5BH 06302734 Planwell House Lefa Business Park. Edgington Way. Sid¢up. KenL DA14 SBH C6300759 Pknwdl Hovse Lela Business Park. Edgin9tTr) Way. Sidcup. Kent. DA14 5BH Allergy England Ltd lo￿￿1> 08494679 Plan￿1 House Lets . Business Pth. EiJgi￿tOn Way. Sfvjcup. Kenl. t)A14 5BH AleTgyScotland Lld SC447980 272 Bath Slreel Glasgcrtv. Ordinary 100% No IDtsmanti G2 4JR Allèrgy Evrope Ltd (Domiantl ￿95950 Planwdl House Lefa Business Park. Edgirig10rt Way. Si(kup. Kent. DA14 5BH Alergy N¢rthem Ir¥laThd Ltd N1679729 $8, Anlrim Enterprise (Dormanll Agenw. Unit 19 Greystone Road, Anlrim. ￿ftty Antrim, Northem I[eL￿d. BT41 1JZ Allergy Wales Ltd {Dormantl 1345W6 Internaknona House, 10 Churchill Way. Carthff. Unrted Kingdom, CF10 2HE Alergy UK Ltd {Dormanl) OrdNwry I￿)% No Allergy Awa￿ Scheme Ltd (Dormanll Ordinary 100% No Ordinary 100% No Ordinary 100% No Oidinary 100% No Ordinary lo￿ No The financial results of Ihe subsKliars for Ihe year were.. N•mes Income Ex￿ndit￿r0 N¢t assets Aller9y Research Lld Allergy UK Lld IO<Ymanti Allergy Aware Scherne Ltd (DOM￿nI) Allergy England Lld (Dormanl) Allergy Scolland Ltd IDOm)antl Allergy Europe Ltd IDomwntl Allergy Nc¥thern Irdand Ltd Ioormantl Allergy Walgs Ltd (Oomanti 1.317,589 11.317.569) 21,183 Page 40

The Britl$h Allergy Foundation IA company limited by guaAnt•• Not•s to tha fin•n¢lal statements For the year ended 31 March 2023 16. Stocks Group 2023 Grcwp 2022 Chartty 2023 Chanty 2022 Good$ fw resal 761 761 17. D¢btors GT¢UP 2023 Group 2022 Charity 2023 Charity 2022 Duo whhln ono year Trade debtors Amounts owed by group underf*it￿3$ Olher deblofs .214.822 40.993 270.606 2.175 68.105 137.442 8.462 65,147 14.951 65.147 7.470 71.855 Prepayrnenls and accrued iFKerfne 294.920 388,254 211.051 361,879 18. Curr•nt ass•t in¥•stments Group 2023 Group 2022 Charity 2023 Charity 2022 Short tem) deposits 462.249 462.249 460,(K#) P￿e 41

The Brltlsh Alloryy Poundation (A company Ilmltsd by guarant••l Not•$ to lh• flnancial statements For th• year Ond￿ 31 March 2023 19. Cl￿$t01$. Arnounts f•lllng due within one year Group 2023 Group 2022 Charlty Charily 2022 Trad8 creditors. Other taxal￿n and S￿SaI seCur￿Y Other creditors Accrvah deferffjd income 78,216 19,016 1,988 322,239 119.228 61.711 44,61S 19,016 1,988 28,004 23,794 22.822 985 138.579 555,630 421.458 737.554 93.623 186.180 Group 2023 GTOUP 2022 Ch•rlty 2023 Charity 2022 Deferred at 1 April 2023 Resowces delet￿ during the Amounts ￿leaSed from perKrfJs 92.964 194.024 408.184 (92.9641 1315.220) 11024 12,500 118.0241 .899 (78,875) Deferred income at 31 March 2023 194.024 92, 12.500 18,024 Page 42

The British Alleryy Foundation {A Company Ilmtted by guarantee) Notes to the Ilnanclal sLements For ¢h y•ai end￿ 31 March 2023 20. Statement ollunds Sialement of fund$- Current year 8alan¢• at 31 March 2023 Balancè at 1 April 2022 Transfèrs inloul Income Exp•nditsre Unrestricted funds Designated lunds Awareness Campaign Reserve Resource Builjing ReseNe IT Re5eive Fundraising Reserye Fixed A55ei Fund Conlingency Fund Project DeIr￿ry Reserve Public Affairs Campaign Reserve 5.120 1¢10.291 10.1)00 42.562 26.720 466.220 75.000 15.1201 1100,2911 (10.0001 142.5621 (6.830) {2.853 17.037 466.220 175,000) 16.395 14.795 16,395 6,455 Dlgtsl Media Reserve {8.3401 757.103 1248.1431 12,853) 506,107 Balance al 31 March 2023 Balance at 1 April 2022 Transfers o￿l0u1 Incom• Expènditurè General fund$ Geneiol Freg Resep4e Alltrrgy Rese•ch Limited 322.326 21.181 1.402.59D 11.393.784) 1853 333,985 21,181 343.507 1.402.590 (1.393.784) 2.853 355,166 Total Unrestricted fund$ 1.100,610 1A02.$90 11,641,927) 861.273 Paje 43

The Briti$h Allergy Foundalion (A company limlled by 9uarantee) Nol•s to th• financial statem•nts For the.y•ar end*d'31 Alareh 2023 20. Stalem¢nt ol funds l¢ontinu¢d) Balance at 31 March 2023 Bala￿9 al 1 Awil 2022 Trnnsfvrs inlout Incom• Expenditur• RestfSct•d lunds HCP Scouand Training Fund 'Novartis Global Skin &inofi Yovth Nutrity8 prizer Aimmune Garfield Weslon 420 420 1A08 13,261 113.2611 77.583 4.680 77,583 4.6BO 5.529 25.000 (5,529) 112,$00) 12.500 15.089 122,258 131.290) 106,057 Total of lunds 1.115.699 1.524.848 {1.673,217) 967.330 Page 44

The 8¥ltlsh ￿l¢r9Y Foundalion (A company limilod by guarart¢•el Not￿ ¢0 lh¢ fthanclal stat•m•nls For the yèar ended 31 March 2023 20. Statement of funds (¢onlinuedl Stst•ment of fvnds- yior year As fesiats>J Tf8nsfers inlout Balance al 31 March 2022 Balance at As rtstsled As reslaled l Aw'l 2021 Ine4•nE Expenditure Unrestrlcted fund DesTrgnat•d funds Awareness Caffwtgn ReseNe Resource BuildirvJ ReseNe IT Reserve {44.880) 5,120 100.291 10,000 42.562 26,720 466,220 75,0(Kl 100.291 10.OtKJ 50.OCKJ 21.747 466,220 75.000 Fundraising Reserve Fix¢d Asset Fund Conlin9¢ncy Fund Projed Delivery Restrr¥e Public Allairs Canpaign Reserye (T.438) (8,142) 13.115 (33.605} (6.638) so.o {409) 16,395 14,795 Media ReseNe 21.1￿¥ 650 794.448 650 {11Y).7011 62,7C6 757,103 As restated Balance al Transfers 31 March inloul 2022 Balance at As restated As ￿stated - 1 2021 Incon Expenditu G¢neral funds General Free Reserve Al￿rgY Rese¥r¢h Lthiiled 267.818 21.181 1.635.216 (1.S41.352) 139,356> 322.326 21,181 288,999 1.635.216 11.541.352) {39.3561 343,507 Total Unreslricted funds 1.083.447 1.635.866 (1.642,0531 23.350 1.100,610 Page 45

The British Allergy Foundalion IA ¢ompany limited by guarant¢t) Notes to the finan¢lal statements For th• y•ar ended 31 March 2023 stst¢m•nt of funds {¢ontinu•d) As cesLited Tran$fers ithut Balance al 31 March 2022 Bafanc al As reslaled As restated 1 hpn'l 2021 Income Expendituie Re51rktsd funds HCP Scolland Trainw)g Fund Digttal Media Over The Wall- Camp in I Cloud Research Piojed )varti$ Global Skin 6CO 25.OCA) 11801 (1.6501 420 123.350> 1,719 . 58.6LKI (1,7191 {58.6001 13.261 13.261 1.408 85.919 14.669 162.1491 123,350) 15,089 Total of funds 1.169.3e6 1.650.$35 11.704.202) 1,115,699 Th• HCP Ih•alth care prof•s$lonal) S¢olland Training Fund is to en Ilw Ch￿lY lo encourage training in aller9y. by making grants lo committed HCPS lo meet a percenla9e of their Iraining cosls, at a t¥ne when the Heatth Service has reduced th￿.1 funding in thts area. Novartis pfowded funding lo create t%KJ webinars developed for healthcare professional$, particularfy in primary care, to raise •¥areness of CSU as a disease ntst related lo ¥llefgy. wth authoritalive guid8n¢e on management. including onward referra. Also to create an infographic to help present an understandable oveNew of Ihe twtmenl and man•aemenl ol CSU. A leaflet lo inloim palients ol management and care palhways lo new targeled Ireatments. Offering helplul informal•)n lor paI￿nIS lo support their engagèment wih tha'r GP. Global Skln made a gianl for the review ¢f Albrgy UK'S ¢urrent eczèma resources on Allergy UK'S website and update where needed. A pcJcasl on lTrJing with eczema vthh a larget database. along ￿￿th a funds lor a Facebook add for Worfd Eczema Day. Sanofl Youth is in reLab'on io Dew10￿t olywlh En9agemonl wsth AIW. Nutricia is a Sponsorshp to devebp and delNer educational acliwlies that are benefKial to the alkn9iC cLwnmunity. ASmmunt aims to lase awareness with healtFKare profe55K)nals ol the vnpaci of fotyj ¥lkgry and Iho emerging pathways to prevent and mar￿e this condition. Garfleld Weston is lo help fund the operathjn of the Allergy helpline. Pfizer fund is for W￿lL￿1r￿j a l>ooklet.on skin to skn"n. knfiel on Atpoic Èczema a ￿al￿t on Eczma blood moniloring. Page 46

The British Allergy Foundatl¢)n IA company Ilmll•d by guaranlee) Notes to th• financlal statements For the year ended 31 March 2023 21. Sumrnary ol fonds Summary of fund$ • current year Balan¢• at 31 March 2023 Balanco at 1 April 2022 Trnnsf¢rs inlout Income Expèndlturo Designaled funds General lunds Restr￿led.{￿ndS 757.103 1248.1431 343.607 1.402.S90 (1.393.T84) 16m9 122.258 131.2901 12,8531 2.853 506,107 3SS,166 106,067 1.116.699 1,524.848 11,673.2171 967.330 Summary ol lunds. prior year As r&$tated Translers i￿o￿t Balance al 31 March 2022 Bkn al A$ r$staled As r¢slated 1 April 2021 Income Eyndrtur• Oesignaled funds Genw81 funds Reslricled fvrtds 794.448 288.999 85.919 650 1100,701) 1,635,216 {1,541.352) 14,669 162,149> 62,7C6 139,356) 123,3501 757.103 343.507 15.089 1.169.366 1.650.S35 (1.704.202} 1.115,699 Page47

The 8rltl$h Allergy Foundatlo IA Company IlmSled by guarantee) Notes lo the financial statements For the yar end•d 31 Mar¢h 2023 21 Anatysls of net assets belwoen funds Analysls of ngt assets b•twwn fvnds- curront year Unw¢stri¢led R•stri¢tod fund$ funds 2023 2023 Total lund$ 2023 Tangibk fixed assets Intsngibb fLxed assets Fixed asset inveslments Current 0$5els Credit￿5 due within one ye 17,227 92.521 14 1,172,9 (421,4581 17.227 92.521 14 106,057 1.279,026 (421,4581 Total 861.273 106.057 967,330 Analysis of net assets between fund$- prlor y•ar Unreslricted funds 2022 ResliKled funds 2022 Total funds 2022 T8ngibk fixed assets IntsngiblÈ fixed assets Fixed asset investments Current assets Credrtor5 due within year 27.431 130.517 14 27.431 130.S17 14 1,695.291 1737.554) 1.680,202 1737,554} 15,089 Total 1,100.610 15,089 1.115,699 Pffje 48

The Brltish Allergy Foundat5on IA Company Ilmlted by guarantee) Not•s to the financial $talen￿nts For the year ènded 31 Mar¢h 2023 R¢¢onclliallon of n•1 movement In funits to net Cash Ilow from owratln9 a¢tfvllles Group 2023 Gioup 2022 Nel expenditure fcK the year {as per StaleThnt of Financol Actr￿8$) {148.3691 153.667) AdAustments tor: Depre¢iation ¢harges Amortisatson Charges Inleresl re¢eived Profil on di¥)osal of inlang Piofil on disposal of fixed asset$ Increase in stocks Decreasel(Increasel in debtors {DeC￿a$ey1ncrea5e in creditors 8.379 20,093 12,02S) 21,039 {5,691) 17.507 4.416 12rxi) 93,334 1316.0961 1161) 1130.3641 130.382 Net cash used in operathw a¢ll¥itles 1327.071) 127.3631 Aftalysls ol cash and cash equivalents Group 2023 Grtsup 2022 Cash in hand 520.896 846,276 26. Analysis of changes In n•t d•bt At 1 Aprll 2022 Ca$h Ilows At31 Maf¢h 2023 Cash al b8nk and in halrd Liquid in¥estmenls 846,276 (325,3801 2.249 520,896 462,249 1.306.276 1323,1311 983.145 P￿e 49

Th• British Allergy Foundation IA ¢ompany limit•d by guarante•l. N¢t•$ lo th• linanclal statsm•nts For th¢ yèar •nded 31 M•r¢h 2023 26. P•n$lon commitinents ' The Gro￿ cyerales a defined c￿￿"bUt10n pensNJn schm for its emF4)yees. Th&. pension cost charge for the period represents conlrt)vlKJns paydble by the Charty to the scheme arml amounled lo £20.236 12022 - £23.7181. Al Iho balance sheel dal# £N￿ was rewnised as a 1k1￿.1itY owed lo the scheme12022 - £Nill. Opeiatlng leas• commllments At 31 March 2023 the Group and the Chairty had corrmltrn￿S lo make luture rninimum b8a5e payments under non<an¢ellabie opernts'ng lea￿$ as Idlows." Group 2023 Group 2022 Charity 2023 Chariiy 2022 Not later than 1 year Laler than 1 year and not later than 5 yews 92.427 17.824 120,317 110,905 92,427 17,B24 120.317 110,905 110.2S1 231,222 110,251 231,222 28. Related party tran$aclions The charity has not entered irto any relaled paty tfansactK)n during the (2022.. £Nil), nor are there any oulslarHJir•J bal￿¢¢$ bets￿n rdated parties and the Charty al 31 Mar¢h 2023 {2022". £Nil). 29.. Controlling party There is no ullimale contrc41ry pafly. Page 50